Application of (+)-sclerotiorin derivative in anti-mycobacterium medicine

By developing (+)-sclerotiorin derivatives, the problem of the lack of compounds that selectively inhibit mycobacteria in the prior art has been solved, providing a pharmaceutical composition with significant anti-mycobacterial activity and good selectivity for the treatment of diseases such as tuberculosis, achieving safer and more effective therapeutic effects.

CN118994004APending Publication Date: 2024-11-22OCEAN UNIV OF CHINA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410599630.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-17
Filing Date
2024-05-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Current technologies lack compounds that can selectively inhibit mycobacteria, especially compounds with good activity and selectivity against mycobacteria, resulting in poor treatment efficacy for diseases such as tuberculosis and serious drug resistance problems.

Method used

A class of (+)-sclerotiorin derivatives, including its stereoisomers, nitrides, solvates, metabolites, and pharmaceutically acceptable salts, has been developed for the preparation of pharmaceutical compositions to prevent or treat infectious diseases caused by Mycobacterium species, such as tuberculosis.

Benefits of technology

These compounds exhibit significant anti-mycobacterial activity, are stable, have good safety profiles, and show synergistic effects with existing drugs. They have promising clinical application prospects and can effectively prevent or treat infectious diseases caused by mycobacteria.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004840041830000023
    Figure BDA0004840041830000023
  • Figure BDA0004840041830000031
    Figure BDA0004840041830000031
  • Figure BDA0004840041830000111
    Figure BDA0004840041830000111
Patent Text Reader

Abstract

The invention belongs to the field of medicinal chemistry, and particularly relates to application of a (+)-sclerotiorin derivative in the aspect of inhibiting anti-mycobacterium activity. The compound represented by the formula (I) has a selective inhibition effect on mycobacteria (Mycobacterium tuberculosis, Mycobacterium marinum and Mycobacterium smegmatis), has no effect on other fungi and bacteria, and has no cytotoxicity. The compound has a remarkable inhibiting effect on a biofilm of bacteria, and can generate a synergistic effect when being combined with a positive drug. The invention provides an anti-mycobacterium medicine which is characterized in that the compound shown in the formula (I) or pharmaceutically acceptable salt thereof is used for treating diseases caused by mycobacterium bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical technology, and specifically relates to a class of (+)-sclerotiorin derivatives, compositions and uses thereof, wherein the compounds or compositions have the use of selectively inhibiting the activity of mycobacteria and can be used to prevent or treat diseases caused by mycobacteria. Background Art

[0002] The genus Mycobacterium includes a large class of Gram-positive, rod-shaped, acid-fast staining-positive bacteria, including many important pathogens that endanger human health, such as Mycobacterium tuberculosis, Mycobacterium marinum, and Mycobacterium smegmatis. They can cause many diseases, from cough, bronchitis, pneumonia and emphysema to cystic fibrosis, tuberculosis and even death. Taking Mycobacterium tuberculosis as an example, in 2021, the number of deaths from tuberculosis worldwide reached 1.6 million, and resistance to first-line drugs such as isoniazid and rifampicin is becoming more and more serious (WHO. Global tuberculosis report 2022, 2023). Therefore, the world needs safer and more effective new drugs for the treatment of mycobacterial infections.

[0003] (+)-Sclerotiorin is a polyketide natural product first isolated from the fungus Penicillium sclerotiorum. It and its derivatives exhibit a wide range of biological activities, such as antifungal activity, cytotoxic activity, and enzyme inhibition activity (Lin L. et al. J. Agr. Food Chem., 2012, 60, 4480-4491; Hai Y., et al. Eur. J. Med. Chem. 2022, 232, 114166; Somoza, AD, et al. Org. Lett., 2012, 14, 972-975). However, up to now, there is no report on (+)-sclerotiorin derivatives that selectively inhibit antimycobacterial activity in vitro. This patent aims to find a class of compounds that can maintain high antimycobacterial activity and have good selectivity as a drug for clinical use. Summary of the invention

[0004] The following is a summary of some aspects of the present invention, which are not limited thereto. These aspects and other parts are described in more detail below. All references in this specification are incorporated herein by reference in their entirety. When there is a difference between the disclosure of this specification and the referenced documents, the disclosure of this specification shall prevail.

[0005] The present invention provides a new class of (+)-sclerotiorin derivatives for preventing or treating infectious diseases caused by mycobacteria, such as pulmonary tuberculosis, bone tuberculosis, lymph node tuberculosis, lumbar tuberculosis, thoracic tuberculosis, breast tuberculosis, swimming pool granuloma, lung infection, lymph node infection, Buruli ulcer. The compounds of the present invention have significant activity, stable properties, good safety, can produce significant synergistic effects with commercially available positive drugs, have good kinetic properties, and therefore have good clinical application prospects.

[0006] The present invention also provides pharmaceutical compositions comprising these compounds and methods of using these compounds or compositions to treat the above diseases in mammals, especially humans.

[0007] Specifically: In one aspect, the present invention relates to a compound as represented by formula (I) or a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, ester, pharmaceutically acceptable salt or prodrug thereof of the compound as represented by formula (I), in: R1 is a substituted or unsubstituted biphenyl, biphenyl ether, terphenyl, 4-(1-naphthyl)phenyl or 4-pyridineamide fragment, wherein the benzene ring and the pyridine ring can be independently and optionally substituted by 1, 2, 3 or 4 groups selected from deuterium, F, Cl, Br, I, hydroxyl, amino, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 3-6 R2 is substituted by a cycloalkyl, a 3-6 membered heterocyclic group, an aryl or a 5-6 membered heteroaryl substituent. R2 is substituted or unsubstituted acetoxy, cinnamate, pyridine acrylate, heterocyclic acrylate, benzoate, pyridine carboxylate and heterocyclic carboxylate, wherein the benzene ring and the pyridine ring can be independently and optionally substituted by 1, 2, 3 or 4 groups selected from deuterium, F, Cl, Br, I, hydroxyl, amino, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 3-6 The substituents are substituted by cycloalkyl, 3-6 membered heterocyclyl, aryl or 5-6 membered heteroaryl.

[0008] The compound according to claim 1, wherein R1 is R2 is hydroxyl, acetoxy, substituted or unsubstituted

[0009] In another aspect, the present invention relates to a pharmaceutical composition comprising a compound disclosed in the present invention.

[0010] In some embodiments, the pharmaceutical composition described in the present invention further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, solvent or a combination thereof.

[0011] On the other hand, the present invention relates to a compound or pharmaceutical composition disclosed in the present invention for preventing or treating infectious diseases caused by Mycobacterium in mammals, including humans; wherein the infectious diseases include pulmonary tuberculosis, bone tuberculosis, lymph node tuberculosis, lumbar tuberculosis, thoracic tuberculosis, breast tuberculosis, swimming pool granuloma, pneumonia, lymph node infection, and Buruli ulcer.

[0012] The biological test results show that the compounds provided by the present invention can inhibit the growth of mycobacteria.

[0013] Any embodiment of any aspect of the present invention can be combined with other embodiments, as long as they do not conflict. In addition, in any embodiment of any aspect of the present invention, any technical feature can be applied to the technical features in other embodiments, as long as they do not conflict.

[0014] The foregoing description only summarizes certain aspects of the present invention, but is not limited to these aspects. These aspects and other aspects will be described in more detail and complete below.

[0015] Detailed description of the invention Definitions and general terms Certain embodiments of the present invention are now described in detail, examples of which are illustrated by the accompanying structural formulas and chemical formulae. The present invention is intended to encompass all substitutions, modifications, and equivalent technical solutions, which are all included within the scope of the present invention as defined in the claims. It should be appreciated by those skilled in the art that many methods and materials similar or equivalent to those described herein can be used to practice the present invention. The present invention is in no way limited to the methods and materials described herein. In the event that one or more of the combined documents, patents, and similar materials differ from or contradict the present application (including but not limited to defined terms, term applications, described technologies, etc.), the present application shall prevail.

[0016] It should be further appreciated that certain features of the invention, which for clarity are described in multiple separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which for brevity are described in a single embodiment, may also be provided separately or in any suitable sub-combination.

[0017] Unless otherwise specified, all technical terms used in the present invention have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. All patents and publications related to the present invention are incorporated herein by reference in their entirety.

[0018] Unless otherwise indicated, the following definitions used herein shall apply. For purposes of the present invention, chemical elements are consistent with the Periodic Table of the Elements, CAS version, and Handbook of Chemistry and Physics, 75th edition, 1994. In addition, general principles of organic chemistry can be found in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry" by Michael B. Smith and Jerry March, John Wiley & Sons, New York: 2007, the entire contents of which are incorporated herein by reference.

[0019] Unless otherwise specified or there is a clear conflict in context, the articles "a", "an", and "the" as used herein are intended to include "at least one" or "one or more". Therefore, these articles as used herein refer to articles that refer to one or more than one (i.e., at least one) of the objects. For example, "a component" refers to one or more components, i.e., there may be more than one component contemplated for use or use in the implementation of the described embodiment.

[0020] The term "subject" as used in the present invention refers to an animal. Typically, the animal is a mammal. Subjects, for example, also refer to primates (e.g., humans, male or female), cattle, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, etc. In certain embodiments, the subject is a primate. In other embodiments, the subject is a human.

[0021] The term "patient" used in the present invention refers to humans (including adults and children) or other animals. In some embodiments, "patient" refers to humans.

[0022] The term "comprising" is an open expression, that is, including the contents specified in the present invention but not excluding other contents.

[0023] "Stereoisomers" refer to compounds that have the same chemical constitution but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, and the like.

[0024] "Chiral" refers to a molecule that is non-superimposable on its mirror image; "achiral" refers to a molecule that is superimposable on its mirror image.

[0025] "Enantiomers" refer to two non-superimposable isomers of a compound that are mirror images of each other.

[0026] "Diastereoisomers" refers to stereoisomers that have two or more chiral centers and whose molecules are not mirror images of each other. Diastereoisomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity. Diastereomeric mixtures can be separated by high resolution analytical procedures such as electrophoresis and chromatography, for example HPLC.

[0027] The stereochemical definitions and conventions used herein generally follow SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994.

[0028] Many organic compounds exist in optically active forms, i.e. they have the ability to rotate the plane of plane polarized light. When describing an optically active compound, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are the symbols used to designate the rotation of plane polarized light caused by the compound, where (-) or l indicates that the compound is left-handed. Compounds prefixed with (+) or d are right-handed. A specific stereoisomer is an enantiomer, and a mixture of such isomers is called a mixture of enantiomers. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which can occur when there is no stereoselectivity or stereospecificity during a chemical reaction.

[0029] Any asymmetric atom (e.g., carbon, etc.) of the compounds disclosed herein can exist in a racemic or enantiomerically enriched form, such as in the (R)-, (S)-, or (R,S)-configuration. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in terms of the (R)- or (S)-configuration.

[0030] Depending on the choice of starting materials and process, the compounds of the invention may exist in the form of one of the possible isomers or a mixture thereof, such as a racemate and a diastereomeric mixture (depending on the number of asymmetric carbon atoms). Optically active (R)- or (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituents may be in the E or Z configuration; if the compound contains a disubstituted cycloalkyl group, the cycloalkyl substituents may be in the cis or trans configuration.

[0031] Any resulting mixture of stereoisomers can be separated into the pure or substantially pure geometric isomers, enantiomers, diastereomers on the basis of the differences in the constituent physicochemical properties, for example, by chromatography and / or fractional crystallization.

[0032] Any racemate of the resulting final product or intermediate can be separated into optical antipodes by known methods by methods familiar to those skilled in the art, such as by separation of the diastereomeric salts obtained. The racemic products can also be separated by chiral chromatography, such as high performance liquid chromatography (HPLC) using a chiral adsorbent. In particular, enantiomers can be prepared by asymmetric synthesis, for example, see Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Principles of Asymmetric Synthesis (2 nd Ed.Robert E.Gawley, Jeffrey Aubé, Elsevier, Oxford, UK, 2012); Eliel, ELStereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, SHTables of Resolving Agents and Optical Resolutions p.268 (ELEliel, Ed., Univ. of NotreDame Press, Notre Dame, IN 1972); Chiral Separation Techniques: A Practical Approach (Subramanian, G.Ed., Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2007).

[0033] As described herein, the compounds of the present invention may be optionally substituted with one or more substituents, such as the above general formula compounds, or as the specific examples, subclasses, and classes of compounds included in the embodiments.

[0034] In general, the term "substituted" means that one or more hydrogen atoms in a given structure are replaced by a substituent as described herein. Unless otherwise indicated, a substituted group may have a substituent substituted at each substitutable position of the group. When more than one position in a given structure can be substituted by one or more substituents selected from a specific group, the substituents may be substituted the same or differently at each position.

[0035] The term "unsubstituted" means that the designated group bears no substituents.

[0036] The term "optionally substituted by..." can be used interchangeably with the term "unsubstituted or substituted by...", i.e., the structure is unsubstituted or substituted by one or more substituents described in the present invention. Substituents described in the present invention include, but are not limited to, D, F, Cl, Br, I, N3, CN, NO2, OH, SH, NH2, alkyl, haloalkyl, alkenyl, alkynyl, alkoxy, alkylamino, cycloalkyl, heterocyclyl, aryl, heteroaryl, and the like.

[0037] In addition, it should be noted that, unless explicitly stated otherwise, the description methods used in the present invention, "each... is independently" and "... are each independently" and "... are independently" can be interchanged and should be understood in a broad sense, which can mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other.

[0038] In various parts of this specification, the substituents of the compounds disclosed in the present invention are disclosed according to group types or ranges. It is particularly pointed out that the present invention includes each independent subcombination of the individual members of these group types and ranges. For example, the term "C 1-6 "Alkyl" specifically refers to methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl as disclosed independently.

[0039] In various parts of the present invention, linking substituents are described. When the structure clearly requires a linking group, the Markush variable listed for that group should be understood as a linking group. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl", it should be understood that the "alkyl" or "aryl" represents an alkylene group or an arylene group, respectively, that is linked.

[0040] The term "alkyl" or "alkyl group" as used herein refers to a saturated straight or branched monovalent hydrocarbon group, wherein the alkyl group may be optionally substituted with one or more substituents described herein. Unless otherwise specified, the alkyl group contains 1-20 carbon atoms. In one embodiment, the alkyl group contains 1-12 carbon atoms; in another embodiment, the alkyl group contains 3-12 carbon atoms; in another embodiment, the alkyl group contains 1-6 carbon atoms; in yet another embodiment, the alkyl group contains 1-4 carbon atoms.

[0041] Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), n-propyl (n-Pr, -CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2), n-butyl (n-Bu, -CH2CH2CH2CH3), isobutyl (i-Bu, -CH2CH(CH3)2), sec-butyl (s-Bu, -CH(CH3)CH2CH3), tert-butyl (t-Bu, -CH(CH3)CH2CH3), u, -C(CH3)3), n-pentyl (-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1 -butyl (-CH2CH(CH3)CH2CH3), n-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3 ), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), n-heptyl, n-octyl, and the like.

[0042] The term "alkoxy" means an alkyl group attached to the rest of the molecule via an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy group contains 1-12 carbon atoms. In one embodiment, the alkoxy group contains 1-6 carbon atoms; in another embodiment, the alkoxy group contains 1-4 carbon atoms; in yet another embodiment, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents as described herein.

[0043] Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), 1-propoxy (n-PrO, n-propoxy, -OCH2CH2CH3), 2-propoxy (i-PrO, i-propoxy, -OCH(CH3)2), 1-butoxy (n-BuO, n-butoxy, -OCH2CH2CH2CH3), 2-methyl-1-propoxy (i-BuO, i-butoxy, -OCH2CH(CH3)2), 2-butoxy (s-BuO, s-butoxy, -OCH(CH3)CH2CH3), 2-methyl-2- Propoxy (t-BuO, t-butoxy, -OC(CH3)3), 1-pentyloxy (n-pentyloxy, -OCH2CH2CH2CH2CH3), 2-pentyloxy (-OCH(CH3)CH2CH2CH3), 3-pentyloxy (-OCH(CH2CH3)2), 2-methyl-2-butoxy (-OC(CH3)2CH2CH3), 3-methyl-2-butoxy (-OCH(CH3)CH(CH3)2), 3-methyl-l-butoxy (-OCH2CH2CH(CH3)2), 2-methyl-l-butoxy (-OCH2CH(CH3)CH2CH3), and the like.

[0044] The term "haloalkyl" means an alkyl group substituted by one or more halogen atoms, wherein the alkyl group has the meaning described herein, and such examples include, but are not limited to, trifluoromethyl, 2,2,3,3-tetrafluoropropyl, and the like.

[0045] The term "cycloalkyl" refers to a monovalent or polyvalent saturated monocyclic, bicyclic or tricyclic hydrocarbon group containing 3 to 12 carbon atoms. In one embodiment, the cycloalkyl group contains 7 to 12 carbon atoms; in another embodiment, the cycloalkyl group contains 3 to 8 carbon atoms; in another embodiment, the cycloalkyl group contains 3 to 6 carbon atoms. The cycloalkyl group may be independently unsubstituted or substituted with one or more substituents described herein.

[0046] The term "heterocyclyl" refers to a saturated or partially unsaturated non-aromatic monocyclic, bicyclic or tricyclic ring containing 3-12 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. Unless otherwise specified, the heterocyclic group can be connected to other groups in the molecule through a carbon atom or through a nitrogen atom, and the -CH2- group can be optionally replaced by -C(=O)-. The sulfur atom of the ring can be optionally oxidized to S-oxide. The nitrogen atom of the ring can be optionally oxidized to N-oxygen compound. Examples of heterocyclic groups include, but are not limited to, oxirane, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxolane, dithiolanyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, homopiperazinyl, homopiperidinyl, diazepanyl, oxepanyl, thiepanyl, oxazepine Base, diazepine Thiazepine Examples of heterocyclic groups in which the -CH2- group is replaced by -C(=O)- include, but are not limited to, 2-oxopyrrolidinyl, oxo-1,3-thiazolidinyl, 2-piperidinone, 3,5-dioxopiperidinyl and pyrimidinedione. Examples of heterocyclic groups in which the sulfur atom is oxidized include, but are not limited to, cyclopentane sulfone and 1,1-dioxothiomorpholinyl. The heterocyclic group may be optionally substituted by one or more substituents described herein.

[0047] As used herein, the term "unsaturated" means that the group contains one or more degrees of unsaturation.

[0048] The term "halogen" or "halogen atom" refers to a fluorine atom (F), a chlorine atom (Cl), a bromine atom (Br) or an iodine atom (I).

[0049] The term "cyano" or "CN" refers to a cyano structure, which group may be attached to other groups.

[0050] The term "aryl" refers to a monovalent or polyvalent monocyclic, bicyclic or tricyclic all-carbon ring system containing 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, wherein at least one ring is aromatic and has one or more points of attachment to the rest of the molecule. In one embodiment, an aryl group is a monovalent or polyvalent carbon ring system consisting of 6-10 ring atoms and containing at least one aromatic ring. Examples of aryl groups may include phenyl, naphthyl and anthracenyl. The aryl group may be independently optionally substituted with one or more substituents described herein.

[0051] The term "heteroaryl" refers to a monovalent or multivalent monocyclic, bicyclic or tricyclic ring containing 5-12 ring atoms, or 5-10 ring atoms, or 5-6 ring atoms, wherein at least one ring is aromatic, and at least one aromatic ring contains one or more heteroatoms and has one or more points of attachment to the rest of the molecule. The heteroaryl group is optionally substituted with one or more substituents described herein. In one embodiment, the heteroaryl group is a heteroaryl group consisting of 5-12 atoms containing 1, 2, 3 or 4 heteroatoms independently selected from O, S and N; in another embodiment, the heteroaryl group is a heteroaryl group consisting of 5-6 atoms containing 1, 2, 3 or 4 heteroatoms independently selected from O, S and N.

[0052] Examples of heteroaryl groups include, but are not limited to, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, oxadiazolyl (e.g., 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl), oxatriazolyl (e.g., 1,2,3,4-oxatriazolyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, isothiazolyl, 2-thiadiazole, 4-thiazolyl, 5-thiazolyl, oxazolyl (e.g. 1,3,4-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl), thiatriazolyl (e.g. 1,2,3,4-thiatriazolyl), tetrazolyl (e.g. 2H-1,2,3,4-tetrazolyl, 1H-1,2,3,4-tetrazolyl), triazolyl (e.g. 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 4H-1,2,4-triazolyl), 2-thienyl, 3-thienyl, 1H-pyrazolyl (e.g. 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl), N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, pyridazinyl (such as 3-pyridazinyl, 4-pyridazinyl), 2-pyrazinyl, triazinyl (such as 1,3,5-triazine), tetrazinyl (such as 1,2,4,5-tetrazine, 1,2,3,5-tetrazine); also include the following bicyclic rings, but are by no means limited to these bicyclic rings: benzimidazolyl, benzofuranyl, benzothiophenyl, indolyl (such as 2-indolyl ), purinyl, quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl), isoquinolyl (e.g., 1-isoquinolyl, 3-isoquinolyl or 4-isoquinolyl), imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, and the like.

[0053] The "pharmaceutically acceptable salt" used in the present invention refers to organic salts and inorganic salts of the compounds of the present invention. Pharmaceutically acceptable salts are well known in the art, as described in the literature: SM Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1-19. Pharmaceutically acceptable salts formed by non-toxic acids include, but are not limited to, inorganic acid salts formed by reaction with amino groups, such as hydrochlorides, hydrobromides, phosphates, sulfates, perchlorates, and organic acid salts such as acetates, oxalates, maleates, tartrates, citrates, succinates, malonates, or other methods described in books and literature, such as ion exchange methods, to obtain these salts. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cyclopentylpropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, stearate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 The present invention also contemplates quaternary ammonium salts formed by any compound containing a N group. Water-soluble or oil-soluble or dispersible products can be obtained by quaternization. Alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Pharmaceutically acceptable salts further include appropriate, non-toxic ammonium, quaternary ammonium salts and amine cations formed by counter ions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C 1-8 Sulfonates and aromatic sulfonates.

[0054] The "solvate" of the present invention refers to an association formed by one or more solvent molecules and the compound of the present invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid and aminoethanol. The term "hydrate" refers to an association formed by the solvent molecule being water.

[0055] When the solvent is water, the term "hydrate" may be used. In some embodiments, one molecule of the compound of the present invention may be combined with one water molecule, such as a monohydrate; in other embodiments, one molecule of the compound of the present invention may be combined with more than one water molecule, such as a dihydrate, and in still other embodiments, one molecule of the compound of the present invention may be combined with less than one water molecule, such as a hemihydrate. It should be noted that the hydrates of the present invention retain the biological effectiveness of the non-hydrated form of the compound.

[0056] As used in the present invention, the term "treatment" of any disease or condition refers to all diseases or conditions that can be slowed down, interrupted, prevented, controlled or stopped, but does not necessarily mean that all symptoms of all diseases or conditions disappear, and it also includes preventive treatment of the symptoms, especially in patients who are prone to such diseases or disorders. In some embodiments, it refers to improving the disease or condition (i.e., slowing down or preventing or alleviating the development of the disease or at least one clinical symptom thereof). In other embodiments, "treatment" refers to alleviating or improving at least one physical parameter, including physical parameters that may not be perceived by the patient. In other embodiments, "treatment" refers to regulating the disease or condition physically (e.g., stabilizing perceptible symptoms) or physiologically (e.g., stabilizing physical parameters) or both. In other embodiments, "treatment" refers to preventing or delaying the onset, occurrence or deterioration of a disease or condition.

[0057] As used herein, the term "therapeutically effective amount" or "therapeutically effective dose" refers to the amount of the compound of the present invention that can induce a biological or medical response in an individual (e.g., reducing or inhibiting enzyme or protein activity, or improving symptoms, alleviating symptoms, slowing or delaying disease progression, or preventing disease, etc.). In one non-limiting embodiment, the term "therapeutically effective amount" refers to an amount that, when administered to an individual, is effective for: (1) at least partially alleviating, inhibiting, preventing and / or ameliorating mycobacterial infection. In another embodiment, the term "therapeutically effective amount" refers to an amount of an effective compound of the present invention that, when administered to a cell, or an organ, or a non-cellular biological substance, or a medium, can at least partially reduce or inhibit mycobacterial infection.

[0058] As used herein, the terms "administering" and "administering" a compound should be understood as providing a compound of the invention or a prodrug of a compound of the invention to an individual in need thereof. It should be recognized that one skilled in the art can affect mycobacterial infection by treating a patient currently suffering from the disorder or prophylactically treating a patient suffering from the disorder with an effective amount of a compound of the invention.

[0059] The term "composition" as used in the present invention refers to a product containing a specified amount of a specified component, and any product directly or indirectly produced by a combination of specified amounts of specified components. The meaning of this term related to a pharmaceutical composition includes a product containing an active ingredient (single or multiple) and an inert ingredient (single or multiple) constituting a carrier, and any product directly or indirectly produced by mixing, compounding or aggregating any two or more components, or by decomposing one or more components, or by other types of reactions or interactions of one or more components. Therefore, the pharmaceutical composition of the present invention includes any composition prepared by mixing a compound of the present invention with a pharmaceutically acceptable carrier.

[0060] Description of the compounds of the present invention The present invention discloses a class of (+)-sclerotiorin derivatives, stereoisomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical preparations and compositions thereof, which can be used for preventing or treating infectious diseases caused by Mycobacterium bacteria, such as pulmonary tuberculosis, bone tuberculosis, lymph node tuberculosis, lumbar tuberculosis, thoracic tuberculosis, breast tuberculosis, swimming pool granuloma, lung infection, lymph node infection and Buruli ulcer.

[0061] In one aspect, the present invention relates to a compound as represented by formula (I) or a stereoisomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof of the compound as represented by formula (I), R1 is a substituted or unsubstituted biphenyl, biphenyl ether, terphenyl, 4-(1-naphthyl)phenyl or 4-pyridineamide fragment, wherein the benzene ring and the pyridine ring can be independently and optionally substituted by 1, 2, 3 or 4 groups selected from deuterium, F, Cl, Br, I, hydroxyl, amino, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 3-6 R2 is substituted by a cycloalkyl, a 3-6 membered heterocyclic group, an aryl or a 5-6 membered heteroaryl substituent. R2 is substituted or unsubstituted cinnamate, pyridine acrylate, heterocyclic acrylate, benzoate, pyridine carboxylate and heterocyclic carboxylate, wherein the benzene ring and the pyridine ring can be independently and optionally substituted by 1, 2, 3 or 4 groups selected from deuterium, F, Cl, Br, I, hydroxyl, amino, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, aryl or 5-6 membered heteroaryl; in some embodiments, R1 is R2 is hydroxyl, acetoxy, substituted or unsubstituted

[0062] In some embodiments, the present invention relates to one of the following compounds or its stereoisomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs, but is in no way limited to these compounds:

[0063] The compounds disclosed in the present invention may contain asymmetric or chiral centers and therefore may exist in different stereoisomeric forms. The present invention is intended to make all stereoisomeric forms of the compounds represented by formula (I), including but not limited to diastereomers, enantiomers, atropisomers and geometric (or conformational) isomers, and mixtures thereof such as racemic mixtures, become part of the present invention.

[0064] In structures disclosed herein, when the stereochemistry of any particular chiral atom is not indicated, all stereoisomers of the structure are contemplated within the present invention and are included as compounds disclosed herein. When stereochemistry is indicated by a solid wedge or dashed line representing a particular configuration, the stereoisomers of the structure are thus unambiguous and defined.

[0065] The compound represented by formula (I) may exist in different tautomeric forms, and all these tautomeric forms are included within the scope of the present invention.

[0066] The compound shown in formula (I) may exist in the form of a salt. In one embodiment, the salt refers to a pharmaceutically acceptable salt. The term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammal treated therewith. In another embodiment, the salt is not necessarily a pharmaceutically acceptable salt, and may be an intermediate for preparing and / or purifying the compound shown in formula (I) and / or for separating the enantiomers of the compound shown in this formula (I).

[0067] Pharmaceutically acceptable acid addition salts can be formed by the action of the compounds disclosed herein with inorganic or organic acids, such as acetate, aspartate, benzoate, benzenesulfonate, bromide / hydrobromide, bicarbonate / carbonate, bisulfate / sulfate, camphorsulfonate, chloride / hydrochloride, chlorophylline, citrate, edisylate, fumarate, glucoheptonate, gluconate, glucuronate, hippurate, hydroiodide / iodide, isethionate, lactate, lactobionate, lauryl sulfate, malate, maleate, malonate, mandelate, methanesulfonate, methylsulfate, naphthoate, naphthylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, polygalactonate, propionate, stearate, succinate, sulfosalicylate, tartrate, toluenesulfonate and trifluoroacetate.

[0068] Pharmaceutically acceptable base addition salts can be formed by reacting the compounds disclosed in the present invention with inorganic bases or organic bases.

[0069] Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from Groups I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium, and magnesium salts.

[0070] Organic bases from which salts can be derived include primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include, for example, isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine, and tromethamine.

[0071] The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound, the basic or acidic part by conventional chemical methods. In general, such salts can be prepared by reacting the free acid form of these compounds with a stoichiometric amount of a suitable base (such as a hydroxide, carbonate, bicarbonate, etc. of Na, Ca, Mg or K), or by reacting the free base form of these compounds with a stoichiometric amount of a suitable acid. Such reactions are usually carried out in water or an organic solvent or a mixture of the two. Generally, in appropriate cases, it is necessary to use a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile. For example, "Remington's Pharmaceutical Sciences", 20th edition, Mack Publishing Company, Easton, Pa., (1985); and "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002) can be found in some other suitable salt lists.

[0072] In addition, the compounds disclosed in the present invention, including their salts, can also be obtained in the form of their hydrates or in the form of solvents (e.g., ethanol, DMSO, etc.) for their crystallization. The compounds disclosed in the present invention can inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, the present invention is intended to include both solvated and unsolvated forms of the compounds disclosed in the present invention.

[0073] Any structural formula given herein is also intended to represent non-isotopically enriched forms of these compounds as well as isotopically enriched forms. Isotopically enriched compounds have structures depicted by the general formula given herein except that one or more atoms are replaced by atoms having a selected atomic mass or mass number. Exemplary isotopes that can be introduced into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 18 F. 31 P. 32 P. 35 S. 36 Cl and 125 I.

[0074] In another aspect, the compounds of the invention include isotopically enriched compounds as defined herein, for example, wherein a radioactive isotope is present, such as 3 H. 14 C and 18 Those compounds of F, or in which non-radioactive isotopes are present, such as 2 H and 13 C. Such isotopically enriched compounds can be used for metabolic studies (using 14 C), reaction kinetics studies (using e.g. 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single photon emission computed tomography (SPECT) including drug or substrate tissue distribution determination, or may be used in radiation therapy of the patient. 18 F-enriched compounds are particularly ideal for PET or SPECT studies. Isotopically enriched compounds of formula (I) can be prepared by conventional techniques familiar to those skilled in the art or by using suitable isotopically labeled reagents to replace the unlabeled reagents used originally as described in the examples and preparations of the present invention.

[0075] In addition, heavier isotopes, especially deuterium (i.e. 2 H or D) can provide certain therapeutic advantages, which are brought about by higher metabolic stability. For example, increased half-life in vivo or reduced dosage requirements or improved therapeutic index. It should be understood that deuterium in the present invention is regarded as a substituent of the compound shown in formula (I). The concentration of such heavier isotopes, especially deuterium, can be defined by isotopic enrichment factors. The term "isotopic enrichment factor" used in the present invention refers to the ratio between the isotopic abundance and the natural abundance of a specified isotope. Where a substituent of a compound of the invention is designated as deuterium, the compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation). Pharmaceutically acceptable solvates according to the invention include those wherein the solvent of crystallization may be isotopically substituted, for example D2O, acetone-d6, DMSO-d6.

[0076] On the other hand, the present invention provides a pharmaceutical composition comprising a compound of the present invention. In one embodiment, the pharmaceutical composition of the present invention further comprises a pharmaceutically acceptable carrier, excipient, adjuvant, solvent or a combination thereof. In another embodiment, the pharmaceutical composition can be a liquid, solid, semi-solid, gel or spray dosage form.

[0077] Pharmaceutical compositions, preparations and administration of the compounds of the present invention The present invention provides a pharmaceutical composition comprising a compound disclosed in the present invention, such as the compound listed in the examples; and a pharmaceutically acceptable excipient, carrier, adjuvant, solvent or a combination thereof.

[0078] The present invention provides a method for treating, preventing or ameliorating a disease or condition, comprising administering a safe and effective amount of a combination drug comprising a compound disclosed in the present invention and one or more therapeutically active agents. The combination drug comprises one or more drugs for preventing or treating tuberculosis, swimming pool granuloma, lung infection, lymph node infection, Buruli ulcer, and the active ingredient of the drug is different from the compound disclosed in the present invention.

[0079] Drugs for the prevention or treatment of tuberculosis, swimming pool granuloma, lung infection, lymph node infection, Buruli ulcer include, but are not limited to, isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, aminosalicylic acid, ethionamide, capreomycin, rifadin, bedaquiline, pretomanid, triclosan, delamanid, and linezolid, or any combination thereof.

[0080] The dosage of the active ingredient in the composition of the present invention can be varied, however, the amount of the active ingredient must be an amount that can obtain a suitable dosage form. The active ingredient can be administered to patients (animals and humans) in need of such treatment at a dosage that provides optimal drug efficacy. The selected dosage depends on the desired therapeutic effect, the route of administration and the duration of treatment. The dosage will vary from patient to patient, depending on the nature and severity of the disease, the weight of the patient, the patient's specific diet, the drugs used at the same time, and other factors that will be recognized by those skilled in the art. The dosage range is generally about 0.5 mg to 1.0 g per patient per day, and can be administered in the form of a single dose or multiple doses. In one embodiment, the dosage range is about 0.5 mg to 500 mg per patient per day; in another embodiment, about 0.5 mg to 200 mg per patient per day; in yet another embodiment, about 5 mg to 50 mg per patient per day.

[0081] It should also be recognized that certain compounds of the present invention may exist in free form and be used therapeutically, or, if appropriate, in the form of pharmaceutically acceptable derivatives thereof. Pharmaceutically acceptable derivatives include pharmaceutically acceptable prodrugs, salts, esters, salts of such esters, or any other adducts or derivatives that, when administered to a patient in need thereof, provide directly or indirectly a compound of the present invention or a metabolite or residue thereof.

[0082] The medicine or pharmaceutical composition disclosed in the present invention can be prepared and packaged in bulk form, wherein a safe and effective amount of the compound shown in formula (I) can be extracted, and then administered to the patient in the form of powder or syrup. Typically, the dosage level between 0.0001 and 10 mg / kg body weight per day is administered to the patient to obtain an effective effect. Alternatively, the pharmaceutical composition disclosed in the present invention can be prepared and packaged as a unit dosage form, wherein each physically discrete unit contains a safe and effective amount of the compound shown in formula (I). When prepared in a unit dosage form, the pharmaceutical composition disclosed in the present invention can generally contain, for example, 0.5 mg to 1 g, or 1 mg to 700 mg, or 5 mg to 100 mg of the compound disclosed in the present invention.

[0083] When the pharmaceutical composition of the present invention contains one or more other active ingredients in addition to the compound of the present invention, the compound weight ratio of the compound of the present invention to the second active ingredient can vary and depends on the effective dose of each component. Usually, an effective dose of each is used. Therefore, for example, when the compound of the present invention is mixed with another medicament, the weight ratio of the compound of the present invention to the other medicament ranges from about 1000:1 to about 1:1000, such as about 200:1 to about 1:200. The mixture of the compound of the present invention and other active ingredients is also usually within the above range, but in each case, the effective dose of each active ingredient should be used.

[0084] As used herein, "pharmaceutically acceptable excipient" means a pharmaceutically acceptable material, mixture or solvent that is relevant to the consistency of the dosage form or pharmaceutical composition. Each excipient must be compatible with the other ingredients of the pharmaceutical composition when mixed to avoid interactions that would significantly reduce the efficacy of the disclosed compounds when administered to a patient and interactions that would result in a pharmaceutical composition that is not pharmaceutically acceptable. In addition, each excipient must be pharmaceutically acceptable, for example, having a sufficiently high purity.

[0085] Suitable pharmaceutically acceptable excipients will vary depending on the specific dosage form selected. In addition, pharmaceutically acceptable excipients may be selected based on their specific function in the composition. For example, certain pharmaceutically acceptable excipients may be selected that can help produce a uniform dosage form. Certain pharmaceutically acceptable excipients may be selected that can help produce a stable dosage form. Certain pharmaceutically acceptable excipients may be selected that help carry or transport the disclosed compounds from one organ or part of the body to another organ or part of the body when administered to a patient. Certain pharmaceutically acceptable excipients may be selected to enhance patient compliance.

[0086] Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, cosolvents, suspending agents, emulsifiers, sweeteners, flavoring agents, taste masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants and buffers. The skilled person will recognize that certain pharmaceutically acceptable excipients can provide more than one function and provide alternative functions, depending on how much of the excipient is present in the formulation and which other excipients are present in the formulation.

[0087] The skilled person has the knowledge and skill in the art to enable them to select a suitable pharmaceutically acceptable excipient for the appropriate amount of the present invention. In addition, there are a large number of resources available to the skilled person that describe pharmaceutically acceptable excipients and are used to select suitable pharmaceutically acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).

[0088] In Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. DB Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and JC Boylan, 1988-1999, Marcel Dekker, New York, various carriers for preparing pharmaceutically acceptable compositions, and the known technology for its preparation are disclosed, and the respective contents of these documents are incorporated into the present invention by reference. Except any conventional carrier medium that is incompatible with the compounds of the present invention (e.g., produces any adverse biological effect or otherwise interacts with any other component in the pharmaceutically acceptable composition in a harmful manner), its use is encompassed within the scope of the present invention.

[0089] The pharmaceutical compositions disclosed in the present invention are prepared using techniques and methods known to those skilled in the art. Some common methods described in the art can be found in Remington's Pharmaceutical Sciences (Mack Publishing Company).

[0090] Therefore, in another aspect, the present invention relates to a process for preparing a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient, carrier, adjuvant, solvent or a combination thereof, the process comprising mixing the various ingredients. The pharmaceutical composition comprising a compound disclosed herein can be prepared by mixing at, for example, ambient temperature and atmospheric pressure.

[0091] The compounds disclosed herein are generally formulated into dosage forms suitable for administration to a patient via a desired route. For example, dosage forms include those suitable for the following routes of administration: (1) oral administration, such as tablets, capsules, caplets, pills, lozenges, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration, such as sterile solutions, suspensions, and reconstituted powders; (3) transdermal administration, such as transdermal patches; (4) rectal administration, such as suppositories; (5) inhalation, such as aerosols, solutions, and dry powders; and (6) topical administration, such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.

[0092] The pharmaceutical composition provided by the present invention can be provided in the form of compressed tablets, tablets, chewable lozenges, instant tablets, composite compressed tablets, or enteric-coated tablets, sugar-coated or film-coated tablets. Enteric-coated tablets are compressed tablets coated with a substance that is resistant to gastric acid but dissolves or disintegrates in the intestine, thereby preventing the active ingredient from contacting the acidic environment of the stomach. Enteric coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalate. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which can help mask unpleasant tastes or odors and prevent tablet oxidation. Film-coated tablets are compressed tablets covered with a thin layer or film of a water-soluble substance. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coatings are endowed with the same general characteristics as sugar coatings. Composite compressed tablets are compressed tablets prepared over more than one compression cycle, including multilayer tablets, and compression coatings or dry coating tablets.

[0093] Tablet dosage forms can be prepared from active ingredients in powder, crystal or granular form alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled release polymers, lubricants, diluents and / or colorants. Flavoring agents and sweeteners are particularly useful in forming chewable tablets and lozenges.

[0094] The pharmaceutical composition provided by the present invention can be provided in a soft capsule or a hard capsule, which can be prepared by gelatin, methylcellulose, starch or calcium alginate. The hard gelatin capsule, also referred to as a dry-filled capsule (DFC), consists of two sections, one section is inserted into the other section, and thus the active ingredient is completely encapsulated. Soft elastic capsules (SEC) are soft, spherical shells, such as gelatin shells, which are plasticized by adding glycerol, sorbitol or similar polyols. The soft gelatin shell can contain a preservative to prevent microbial growth. Suitable preservatives are those as described in the present invention, including methylparaben and propylparaben, and sorbic acid. Liquid, semisolid and solid dosage forms provided by the present invention can be encapsulated in a capsule. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239 and 4,410,545. The capsules may also be coated as known to those skilled in the art to improve or sustain dissolution of the active ingredient.

[0095] The pharmaceutical compositions provided by the present invention can be provided in liquid and semisolid dosage forms, including emulsions, solutions, suspensions, elixirs and syrups. Emulsions are two-phase systems in which one liquid is completely dispersed in another liquid in the form of globules, which can be oil-in-water or water-in-oil. Emulsions can include pharmaceutically acceptable non-aqueous liquids and solvents, emulsifiers and preservatives. Suspensions can include pharmaceutically acceptable suspending agents and preservatives. Aqueous alcoholic solutions can include pharmaceutically acceptable acetals, such as di(lower alkyl) acetals of lower alkyl aldehydes, such as acetaldehyde diethyl acetal; and water-soluble solvents having one or more hydroxyl groups, such as propylene glycol and ethanol. Elixirs are transparent, sweet-tasting aqueous alcoholic solutions. Syrups are concentrated sugars such as sucrose in water, and can also contain preservatives. For liquid dosage forms, for example, solutions in polyethylene glycol can be diluted with sufficient pharmaceutically acceptable liquid carriers such as water for accurate and convenient administration.

[0096] Other useful liquid and semisolid dosage forms include, but are not limited to, those containing the active ingredients provided by the present invention and secondary mono- or poly-alkylene glycols, including: 1,2-dimethoxymethane, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether, tetraethylene glycol dimethyl ether, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether, wherein 350, 550, 750 refer to the approximate average molecular weight of polyethylene glycol. These preparations may further include one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarin, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfite, sodium pyrosulfite, thiodipropionic acid and its esters and dithiocarbamates.

[0097] Where appropriate, dosage unit formulations for oral administration may be microencapsulated. They may also be prepared to prolong or sustain the release of the composition, for example, by coating or embedding particulate material in polymers, wax or the like.

[0098] The oral pharmaceutical composition provided by the present invention can also be provided in the form of liposomes, micelles, microspheres or nanosystems. The micelle dosage form can be prepared by the method described in US Pat. No. 6,350,458.

[0099] Pharmaceutical composition provided by the invention can be provided with non-effervescent or effervescent granules and powders to be reconstituted into liquid dosage forms. Pharmaceutically acceptable carriers and excipients used in non-effervescent granules or powders can include diluents, sweeteners and wetting agents. Pharmaceutically acceptable carriers and excipients used in effervescent granules or powders can include organic acids and carbon dioxide sources.

[0100] Coloring and flavoring agents may be used in all of the above dosage forms.

[0101] Compound disclosed by the present invention can also be combined with soluble polymers as targeted drug carriers. Such polymers include polyvinylpyrrolidone, pyran copolymers, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol or the polyoxyethylene polylysine substituted by palmitoyl residues. In addition, compound disclosed by the present invention can be combined with a class of biodegradable polymers used in realizing the controlled release of medicine, for example, crosslinked or amphiphilic block copolymers of polylactic acid, poly-ε-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and hydrogels.

[0102] The pharmaceutical compositions provided by the present invention can be formulated into immediate or modified release dosage forms, including delayed-, sustained-, pulsed-, controlled-, targeted-, and programmed release forms.

[0103] The pharmaceutical composition provided by the present invention can be co-formulated with other active ingredients that do not impair the intended therapeutic effect, or co-formulated with substances that supplement the intended effect.

[0104] Pharmaceutical composition provided by the invention can be administered parenterally by injection, infusion or implantation, for local or systemic administration. Parenteral administration as used in the present invention includes intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, ​​intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous administration.

[0105] Pharmaceutical composition provided by the invention can be formulated into any dosage form suitable for parenteral administration, including solution, suspension, emulsion, micelle, liposome, microsphere, nano system and the solid form suitable for making solution or suspension in liquid before injection. Such dosage form can be prepared according to the conventional method known to the technicians in the field of pharmaceutical science (referring to Remington:The Science and Practice of Pharmacy, the same).

[0106] Pharmaceutical compositions intended for parenteral administration may include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against microbial growth, stabilizers, solution enhancers, isotonicity agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestrants or chelating agents, antifreeze agents, cryoprotectants, thickeners, pH adjusters and inert gases.

[0107] Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringers injection. Non-aqueous vehicles include, but are not limited to, fixed oils of plant origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, medium chain triglycerides of hydrogenated soybean oil and coconut oil, and palm seed oil. Water-miscible vehicles include, but are not limited to, ethanol, 1,3-butylene glycol, liquid polyethylene glycols (e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerol, N-methyl-2-pyrrolidone, N,N-dimethylacetamide and dimethyl sulfoxide.

[0108] Suitable antimicrobial agents or preservatives include, but are not limited to, phenol, cresol, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl parabens, thimerosal, benzalkonium chloride (e.g., benzethonium chloride), methyl and propyl parabens, and sorbic acid. Suitable isotonic agents include, but are not limited to, sodium chloride, glycerol, and glucose. Suitable buffers include, but are not limited to, phosphates and citrates. Suitable antioxidants are those described herein, including bisulfites and sodium metabisulfite. Suitable local anesthetics include, but are not limited to procaine hydrochloride. Suitable suspending agents and dispersing agents are those described herein, including sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable emulsifiers include those described herein, including polyoxyethylene sorbitan monolaurate. Polyoxyethylene sorbitan monooleate 80 and triethanolamine oleate. Suitable sequestrants or chelating agents include, but are not limited to EDTA. Suitable pH adjusters include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not limited to, cyclodextrins, including α-cyclodextrin, β-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutyl ether-β-cyclodextrin, and sulfobutyl ether 7-β-cyclodextrin ( CyDex, Lenexa, KS).

[0109] The pharmaceutical composition provided by the present invention can be formulated into single dose or multiple dose administration. The single dose preparation is packaged in an ampoule, a vial or a syringe. The multiple dose parenteral preparation must contain an antimicrobial agent at a bacteriostatic or antifungal concentration. All parenteral preparations must be sterile, as known and practiced in the art.

[0110] In one embodiment, the pharmaceutical composition is provided as a ready-to-use sterile solution. In another embodiment, the pharmaceutical composition is provided as a sterile dry soluble product, including lyophilized powders and hypodermic tablets, which are reconstituted with a vehicle before use. In yet another embodiment, the pharmaceutical composition is formulated as a ready-to-use sterile suspension. In yet another embodiment, the pharmaceutical composition is formulated as a sterile dry insoluble product that is reconstituted with a vehicle before use. In yet another embodiment, the pharmaceutical composition is formulated as a ready-to-use sterile emulsion.

[0111] The pharmaceutical composition can be formulated as a suspension, solid, semisolid or thixotropic liquid for use as an implanted depot for administration. In one embodiment, the pharmaceutical composition disclosed herein is dispersed in a solid inner matrix, which is surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredients in the pharmaceutical composition to diffuse through.

[0112] Suitable inner matrices include polymethyl methacrylate, polybutyl methyl acrylate, plasticized or unplasticized polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubber, polydimethylsiloxane, silicone carbonate copolymers, hydrophilic polymers such as hydrogels of esters of acrylic acid and methacrylic acid, collagen, cross-linked polyvinyl alcohol, and partially hydrolyzed polyvinyl acetate of coach.

[0113] Suitable outer polymeric films include polyethylene, polypropylene, ethylene / propylene copolymers, ethylene / ethyl acrylate copolymers, ethylene / vinyl acetate copolymers, silicone rubber, polydimethylsiloxane, chloroprene rubber, chlorinated polyethylene, polyvinyl chloride, copolymers of chlorinated ethylene and vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubber, ethylene / vinyl alcohol copolymers, ethylene / vinyl acetate / vinyl alcohol terpolymers, and ethylene / vinyloxyethanol copolymers.

[0114] On the other hand, the pharmaceutical composition disclosed in the present invention can be formulated into any dosage form suitable for inhalation administration to patients, such as dry powder, aerosol, suspension or solution composition. In one embodiment, the pharmaceutical composition disclosed in the present invention can be formulated into a dosage form suitable for inhalation administration to patients using dry powder. In another embodiment, the pharmaceutical composition disclosed in the present invention can be formulated into a dosage form suitable for inhalation administration to patients through a nebulizer. The dry powder composition delivered to the lungs by inhalation generally comprises a fine powder of the compound disclosed in the present invention and one or more fine powdered pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients particularly suitable for use as dry powders are known to those skilled in the art and include lactose, starch, mannitol, and mono-, di- and polysaccharides. Fine powders can be prepared, for example, by micronization and grinding. In general, size-reduced (e.g., micronized) compounds can be prepared by a D of about 1 to 10 microns. 50 values ​​(measured, for example, by laser diffraction).

[0115] Aerosols can be prepared by suspending or dissolving the compounds disclosed in the present invention in a liquefied propellant. Suitable propellants include chlorinated hydrocarbons, hydrocarbons and other liquefied gases. Representative propellants include: trichlorofluoromethane (propellant 11), dichlorofluoromethane (propellant 12), dichlorotetrafluoroethane (propellant 114), tetrafluoroethane (HFA-134a), 1,1-difluoroethane (HFA-152a), difluoromethane (HFA-32), pentafluoroethane (HFA-12), heptafluoropropane (HFA-227a), perfluoropropane, perfluorobutane, perfluoropentane, butane, isobutane and pentane. Aerosols comprising compounds disclosed in the present invention are usually administered to patients by a metered dose inhaler (MDI). Such devices are known to those skilled in the art. Aerosols may contain additional pharmaceutically acceptable excipients that can be used with MDIs, such as surfactants, lubricants, co-solvents and other excipients to improve the physical stability of the formulation, improve valve characteristics, improve solubility, or improve taste.

[0116] Pharmaceutical compositions suitable for transdermal administration can be prepared as discontinuous patches, intended to remain in close contact with the patient's epidermis for an extended period of time. For example, active ingredients can be delivered from the patch by ion permeation, as generally described in Pharmaceutical Research, 3(6), 318(1986).

[0117] The pharmaceutical composition that is suitable for topical administration can be formulated into ointment, cream, suspension, lotion, powder, solution, paste, gel, spray, aerosol or oil.For example, ointment, cream and gel can be prepared with water or oil base, and applicable thickener and / or gel and / or solvent.Such matrix can include, water, and / or oil such as liquid liquid paraffin and vegetable oil (such as peanut oil or castor oil), or solvent such as polyethylene glycol.Thickener and gel used according to matrix properties include soft paraffin, aluminum stearate, cetearyl alcohol, polyethylene glycol, lanolin, beeswax, carboxyvinyl polyol and cellulose derivative, and / or glyceryl monostearate and / or nonionic emulsifier.

[0118] Lotions may be formulated with an aqueous or oily base, and generally also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents or thickening agents.

[0119] Powders for external use may be formulated in the presence of any suitable powder base such as talc, lactose or starch. Drops may be formulated with an aqueous or non-aqueous base containing one or more dispersants, solubilizers, suspending agents or preservatives.

[0120] Topical preparations can be administered by application to the affected area once or more per day; occlusive dressings covering the skin are preferred. Adhesive reservoir systems allow for continuous or prolonged administration.

[0121] Uses of the compounds and compositions of the present invention The compound or pharmaceutical composition disclosed in the present invention can be used to prepare a drug for treating, preventing, improving, controlling or alleviating infectious diseases caused by Mycobacterium bacteria in mammals, including humans.

[0122] Specifically, the compounds of the present invention can be used to prevent or treat infectious diseases caused by Mycobacterium bacteria, including pulmonary tuberculosis, bone tuberculosis, lymph node tuberculosis, lumbar tuberculosis, thoracic tuberculosis, breast tuberculosis, swimming pool granuloma, lung infection, lymph node infection, and Buruli ulcer.

[0123] The compounds or compositions of the present invention can be applied to, but are not limited to, preventing, treating or alleviating diseases caused by Mycobacterium bacteria in mammals, including humans, by administering an effective amount of the compounds or compositions of the present invention to patients.

[0124] The compounds and pharmaceutical compositions of the present invention are useful for human treatment and can also be used in veterinary treatment of pets, introduced species of animals and mammals in farm animals. Other examples of animals include horses, dogs and cats. Here, the compounds of the present invention include pharmaceutically acceptable derivatives thereof.

[0125] Treatment In one embodiment, the treatment method disclosed in the present invention comprises administering a safe and effective amount of a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention to a patient in need. The various embodiments disclosed in the present invention include methods for treating the above-mentioned diseases by administering a safe and effective amount of a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention to a patient in need.

[0126] In one embodiment, the compounds disclosed in the present invention or pharmaceutical compositions comprising the compounds disclosed in the present invention can be administered by any suitable route of administration, including systemic administration and topical administration. Systemic administration includes oral administration, parenteral administration, transdermal administration and rectal administration. Typical parenteral administration refers to administration by injection or infusion, including intravenous, intramuscular and subcutaneous injection or infusion. Topical administration includes application to the skin and intraocular, ear, vaginal, inhalation and intranasal administration. In one embodiment, the compounds disclosed in the present invention or pharmaceutical compositions comprising the compounds disclosed in the present invention can be administered orally. In another embodiment, the compounds disclosed in the present invention or pharmaceutical compositions comprising the compounds disclosed in the present invention can be administered by inhalation. In another embodiment, the compounds disclosed in the present invention or pharmaceutical compositions comprising the compounds disclosed in the present invention can be administered intranasally.

[0127] In one embodiment, the compounds disclosed in the present invention or the pharmaceutical composition comprising the compounds disclosed in the present invention can be administered once, or several times at different time intervals within a specified time period according to the dosing regimen. For example, once, twice, three times or four times a day. In one embodiment, the drug is administered once a day. In another embodiment, the drug is administered twice a day. It can be administered until the desired therapeutic effect is achieved or the desired therapeutic effect is maintained indefinitely. The appropriate dosing regimen of the compounds disclosed in the present invention or the pharmaceutical composition comprising the compounds disclosed in the present invention depends on the pharmacokinetic properties of the compound, such as dilution, distribution and half-life, which can be determined by technicians. In addition, the appropriate dosing regimen of the compounds disclosed in the present invention or the pharmaceutical composition comprising the compounds disclosed in the present invention, including the duration of implementation of the regimen, depends on the disease being treated, the severity of the disease being treated, the age and physical condition of the patient being treated, the medical history of the patient being treated, the nature of the concurrent therapy, the desired therapeutic effect, etc., within the knowledge and experience of the technician. Such technicians should also understand that the dosing regimen of the matter may be required to adjust the individual patient's response to the dosing regimen, or when the individual patient's needs change over time.

[0128] The compounds disclosed in the present invention can be administered simultaneously with one or more other therapeutic agents, or before or after the administration of the compounds disclosed in the present invention. The compounds disclosed in the present invention can be administered separately with other therapeutic agents through the same or different administration routes, or can be administered together with the other therapeutic agents in the form of a pharmaceutical composition.

[0129] For individuals of about 50-70 kg, the pharmaceutical compositions and combinations disclosed herein can be in the form of unit doses containing about 1-1000 mg, or about 1-500 mg, or about 1-250 mg, or about 1-150 mg, or about 0.5-100 mg, or about 1-50 mg of active ingredient. The therapeutically effective amount of the compound, pharmaceutical composition, or combination thereof depends on the species, weight, age, and individual condition of the individual, the disorder or disease being treated, or its severity. A physician, clinician, or veterinarian with common skills can easily determine the effective amount of each active ingredient required to prevent, treat, or inhibit the development of a disorder or disease.

[0130] The above-cited dosage characteristics have been confirmed in in vitro and in vivo tests using advantageous mammals (e.g., mice, rats, dogs, monkeys) or their isolated organs, tissues and specimens. The compounds disclosed in the present invention are used in vitro in the form of solutions, such as aqueous solutions, and can also be used in vivo in the form of suspensions or aqueous solutions, such as enteral, parenteral, and especially intravenous.

[0131] In one embodiment, the therapeutically effective dose of the disclosed compound is about 0.1 mg to about 2,000 mg per day. Its pharmaceutical composition should provide about 0.1 mg to about 2,000 mg of the compound. In a specific embodiment, the prepared drug dosage unit form can provide about 1 mg to about 2,000 mg, about 10 mg to about 1,000 mg, about 20 mg to about 500 mg, or about 25 mg to about 250 mg of the main active ingredient or a combination of the main ingredients in each dosage unit form. In a specific embodiment, the prepared drug dosage unit form can provide about 10 mg, 20 mg, 25 mg, 50 mg, 100 mg, 250 mg, 500 mg, 1000 mg or 2000 mg of the main active ingredient.

[0132] In addition, the compounds disclosed in the present invention can be administered in the form of prodrugs. In the present invention, the "prodrug" of the compounds disclosed in the present invention is a functional derivative that can eventually release the compounds disclosed in the present invention in vivo when administered to a patient. When administering the compounds disclosed in the present invention in the form of prodrugs, those skilled in the art may implement one or more of the following methods: (a) changing the in vivo onset time of the compound; (b) changing the in vivo duration of action of the compound; (c) changing the in vivo transport or distribution of the compound; (d) changing the in vivo solubility of the compound; and (e) overcoming the side effects or other difficulties faced by the compound. Typical functional derivatives used to prepare prodrugs include variants of compounds that are chemically or enzymatically cleaved in vivo. These variants, including the preparation of phosphates, amides, esters, thioesters, carbonates, and carbamates, are well known to those skilled in the art.

[0133] General synthetic steps To describe the present invention, the following examples are listed. However, it should be understood that the present invention is not limited to these examples, which are only provided to provide methods for practicing the present invention.

[0134] Generally, the compounds of the present invention can be prepared by the methods described herein, unless otherwise specified, wherein the substituents are as defined in formula (I). The following reaction schemes and examples are provided to further illustrate the present invention.

[0135] Those skilled in the art will recognize that the chemical reactions described herein can be used to suitably prepare many other compounds of the invention, and that other methods for preparing the compounds of the invention are considered to be within the scope of the invention. For example, the synthesis of the non-exemplified compounds according to the invention can be successfully accomplished by those skilled in the art by modification methods, such as appropriate protection of interfering groups, by utilizing other known reagents in addition to those described herein, or by making some conventional modifications to the reaction conditions. In addition, the reactions disclosed herein or known reaction conditions are also recognized to be applicable to the preparation of other compounds of the invention.

[0136] In the examples described below, all temperatures are in degrees Celsius unless otherwise indicated. Reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Arco Chemical Company and Alfa Chemical Company and were used without further purification unless otherwise indicated. Common reagents were purchased from Shantou Xilong Chemical Factory, Guangdong Guanghua Chemical Reagent Factory, Guangzhou Chemical Reagent Factory, Tianjin Haoyuyu Chemical Co., Ltd., Tianjin Fuchen Chemical Reagent Factory, Wuhan Xinhuayuan Technology Development Co., Ltd., Qingdao Tenglong Chemical Reagent Co., Ltd. and Qingdao Ocean Chemical Factory.

[0137] Anhydrous dichloromethane was obtained by drying under reflux over calcium hydride. Ethyl acetate and petroleum ether were dried over anhydrous sodium sulfate before use.

[0138] The chromatographic column used was a silica gel column, and the silica gel (300-400 mesh) was purchased from Qingdao Ocean Chemical Plant.

[0139] NMR spectra were recorded on a Bruker 400 MHz, 500 MHz or 600 MHz NMR spectrometer using CDCl3, DMSO-d6, CD3OD or acetone-d6 as solvents (in ppm) and TMS (0 ppm) or chloroform (7.26 ppm) as reference standards. When multiple peaks are present, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets). Coupling constants are expressed in Hertz (Hz).

[0140] The following abbreviations are used throughout this invention: CDCl3 deuterated chloroform Methanol-d4 Deuterated methanol DMAP 4-dimethylaminopyridine EDC·HCl 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride mg milligram mmol millimole M mole per liter ℃ Celsius MeOH Methanol mL milliliters rt room temperature Typical synthetic steps for preparing the compounds disclosed in the present invention are shown in the following synthetic scheme 1. Unless otherwise specified, R1 and R2 have the meanings described in the present invention.

[0141] Synthesis Scheme 1 First, the corresponding aniline reagent (1.14mmol) and potassium carbonate (15.8mg, 0.11mmol) were dissolved in 10mL triethylamine solution, and then heated in a water bath at 35°C for 10 minutes, and then the compound (+)-sclerotiorin (150.0mg, 0.38mmol) was added. Then, the entire reaction system was stirred for 2 hours, and the reaction was monitored by thin layer chromatography until a new red product appeared. After the reaction was completed, the reaction mixture was quenched with a saturated ammonium chloride solution, and the reaction solution was extracted with ethyl acetate for more than three times. The organic phases were combined and dried to obtain the corresponding R2 acetoxy (OAc) product.

[0142] Take 100 mg of the product containing acetoxy obtained in the previous step and dissolve it in 6 mL of methanol solution, then add 500 μL of 1 M sodium hydroxide aqueous solution. The reaction system is stirred at room temperature for 0.5 hours. The reaction mixture is quenched with saturated ammonium chloride solution, and the system is adjusted to neutrality with 1 M dilute hydrochloric acid solution. Then, the reaction solution is extracted with ethyl acetate, and the organic phase is collected and spin-dried to obtain the corresponding product in which R2 is hydroxyl (OH).

[0143] The above product (0.17mmol), DMAP (20.7mg, 0.17mmol) and EDC·HCl (130.4mg, 0.68mmol) were dissolved in 15mL of anhydrous dichloromethane, and a small drop of triethylamine was added. After stirring for 5 minutes in a 40℃ water bath, the corresponding carboxylic acid reagent (0.68mmol) was slowly added. The reaction was stirred for 1 to 3 hours, and thin layer chromatography was used to monitor the reaction process until a new red product with less polarity appeared. After the reaction was completed, a saturated ammonium chloride solution was added to terminate the reaction, and the organic phase was separated and concentrated under reduced pressure to obtain a crude extract, and the corresponding compound with R2 being other ester groups was obtained.

[0144] The compounds, pharmaceutical compositions and applications of the present invention are further described below in conjunction with the examples. Example Embodiment 1: (R)-2-([1,1'-biphenyl]-4-yl)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl acetate (Compound 1) Red powder; yield 85%; mp 163–165℃. 1H NMR (500MHz, CDCl3, J in Hz)δ7.88(s,1H),7.78-7.73(m,2H),7.63(d,J=7.2Hz,2H),7.55-7.49(m,2H), 7.36(d,J=7.2Hz,2H),7.18(s,1H),6.99(d,J=14.8Hz,1H),6.92(m,1H),5.68(o verlapped,2H),2.49-2.30(m,1H),2.19(s,3H),1.60(s,3H),1.53(s,3H),1.4 7-1.35(m,1H),1.34-1.31(m,1H),0.99(d,J=6.7Hz,3H),0.85(t,J=7.3Hz,3H). 13 C NMR (125MHz, CDCl3) δ193.7,185.1,170.1,147.8,147.4,143.9,143.1,141.1,139.3,138.9,131.8,130.0,129.1,129.1,128.6 ,128.6,128.4,128.4,127.1,127.1,126.8,116.2,115.3,114.4,109.9,84.7,34.9,29.9,29.6,20.2,20.1,12.2,11.9.HRESIMS m / z 542.2096[M+H] + (calcd for C 33 H 33 ClNO4 + ,542.2098).

[0146] Embodiment 2: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(4'-fluoro-[1,1'-biphenyl]-4-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl acetate (Compound 2) Red powder, yield 81%; mp 135–137℃. 1H NMR(400MHz,CDCl3,J in Hz)δ7.86(s,1H),7.70(d,J=8.0Hz,2H),7.62–7.56(m,2H),7.35(d,J=8.0Hz,2H),7.21–7.13(overlapped,3H),6.96(d,J=15.5Hz,1H),5.73–5.60(overl apped,2H),2.45–2.34(m,1H),2.18(s,3H),1.59(s,3H),1.53(s,3H),1.44– 1.36(m,1H),1.33–1.25(m,1H),0.98(d,J=6.6Hz,3H),0.84(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ193.9,184.8,170.3,162.0(d, 1 J C-F =248.1Hz),148.1,147.6,144.1,143.4,142.1,141.2,139.5,135.3,135.3,131.9,129.0,129.0,128.6,127 .1,127.1,116.4,116.4,116.1,114.6,110.1,103.6,84.9,35.1,30.1,23.3,20.4,20.3,12.4,12.1.HRESIMS m / z 560.2017[M+H] + (calcd for C 33 H 32 ClFNO4 + ,560.2004).

[0147] Embodiment 3: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(4'-fluoro-[1,1'-biphenyl]-4-yl)-7-hydroxy-7-methylisoquinoline-6,8(2H,7H)-dione (Compound 3) Red powder, yield 47%; mp 119–123℃. 1H NMR (400MHz, CDCl3, J in Hz)δ7.87(s,1H),7.71(d,J=8.0Hz,2H),7.62–7.57(m,2H),7.37(d,J=8.0Hz, 2H),7.19(t,J=8.4Hz,2H),7.15(s,1H),7.00(d,J=15.6Hz,1H),5.75–5.67(ov erlapped,2H),4.11(s,1H),2.45–2.36(m,1H),1.61(s,3H),1.54(s,3H),1.42 –1.39(m,1H),1.33–1.31(m,1H),0.98(d,J=6.6Hz,3H),0.85(t,J=7.5Hz,3H). 13 C NMR (100MHz, CDCl3) δ196.5,188.2,160.4,148.5,148.1,145.5,143.8,142.3,140.3,139.4,132.0,129.1,129.0,128.7, 128.7,127.1,127.1,116.4,116.4,116.3,116.2,115.6,109.5,101.0,83.7,35.2,30.1,29.6,20.3,12.5,12.1.HRESIMS m / z 518.1907[M+H] + (calcd for C 31 H 30 ClFNO3 + ,518.1898).

[0148] Embodiment 4: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(4'-fluoro-[1,1'-biphenyl]-4-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl cinnamate (Compound 4) Red powder, yield 40%; mp 136–138℃. 1H NMR(400MHz,Acetone-d6,J in Hz)δ7.96–7.91(overlapped,3H),7.86–7.81(m,2H),7.75–7.68(overlapped,5H),7.48–7.4 4(overlapped,3H),7.32–7.26(overlapped,2H),7.24–7.16(overlapped,2H),6.65(d,J=16 .0Hz,1H),5.86(d,J=15.7Hz,1H),5.78(d,J=9.7Hz,1H),2.51–2.41(m,1H),1.57(s,3H),1.5 6(s,3H),1.45–1.38(m,1H),1.34–1.29(m,1H),0.97(d,J=6.6Hz,3H),0.83(t,J=7.5Hz,3H). 13 C NMR (100MHz, CDCl3) δ193.7,184.2,165.9,148.8,147.7,146.7,144.7,143. 4,142.3,142.2,140.9,135.3,133.2,131.5,130.0,130.0,130.0,130.0,129 .9,129.9,129.3,129.3,129.1,129.1,128.5,128.5,118.0,118.0,116.8,1 16.6,115.2,109.6,103.0,86.1,35.5,30.7,23.6,20.5,12.4,12.2.HRESIMS m / z 648.2297[M+H] + (calcd for C 40 H 36 ClFNO4 + ,648.2317).

[0149] Embodiment 5: (R)-5-chloro-2-(4'-chloro-[1,1'-biphenyl]-4-yl)-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl acetate (Compound 5) Red powder, yield 82%; mp120–121℃. 1H NMR (400MHz, CDCl3, J in Hz)δ7.85(s,1H),7.71(d,J=8.6Hz,2H),7.55(d,J=8.5Hz,2H),7.45(d,J=8.6H z,2H),7.35(d,J=8.5Hz,2H),7.16(s,1H),6.96(d,J=15.5Hz,1H),5.69–5.62(o verlapped,2H),2.44–2.35(m,1H),2.17(s,3H),1.59(s,3H),1.53(s,3H),1.4 5–1.37(m,1H),1.34–1.28(m,1H),0.97(d,J=6.6Hz,3H),0.84(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ193.8,184.8,170.3,148.1,147.5,144.0,143.4,141.8,141.2,139.7,137.5,134.8,131.9,129.4,129.4 ,128.6,128.6,128.5,128.5,127.1,127.1,116.3,114.6,110.1,103.6,84.9,35.1,30.1,23.3,20.4,20.3,12.4,12.1.HRESIMS m / z 576.1720[M+H] + (calcd for C 33 H 32 Cl2NO4 + ,576.1708).

[0150] Embodiment 6: (R)-5-chloro-2-(4'-chloro-[1,1'-biphenyl]-4-yl)-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-hydroxy-7-methylisoquinoline-6,8(2H,7H)-dione (Compound 6) Red powder, yield 74%; mp120–121℃. 1H NMR (400MHz, CDCl3, J in Hz)δ7.86(s,1H),7.72(d,J=8.1Hz,2H),7.55(d,J=8.3Hz,2H),7.46(d,J=8.3H z,2H),7.39(d,J=8.1Hz,2H),7.14(s,1H),7.00(d,J=15.5Hz,1H),5.74–5.66(o verlapped,2H),4.12(s,1H),2.47–2.37(m,1H),1.61(s,3H),1.54(s,3H),1.4 7–1.38(m,1H),1.34–1.28(m,1H),1.00(d,J=6.6Hz,3H),0.84(t,J=7.5Hz,3H). 13 C NMR (100MHz, CDCl3) δ196.5,188.2,148.5,148.1,145.4,143.8,142.0,140.3,139.6,137.5,134.9,132.0,129.5,129.5, 128.7,128.7,128.6,128.6,127.1,127.1,116.3,115.6,109.5,101.0,83.7,35.1,30.1,29.6,20.3,12.5,12.1.HRESIMS m / z 534.1614[M+H] + (calcd for C 31 H 30 Cl2NO3 + ,534.1603).

[0151] Embodiment 7: (R)-5-chloro-2-(4'-cyano-[1,1'-biphenyl]-4-yl)-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl acetate (Compound 7) Red powder, yield 73%; mp123–125℃. 1H NMR(400MHz,CDCl3,J in Hz)δ7.84(s,1H),7.81–7.72(overlapped,6H),7.74(d,J=8.5Hz,2H),7.15(s,1H),6.97(d,J=15.5Hz,1H),5.71–5.61(overlapped,2H),2. 44–2.34(m,1H),2.16(s,3H),1.58(s,3H),1.53(s,3H),1.44–1.36(m,1H),1.34–1.27(m,1H),0.97(d,J=6.6Hz,3H),0.84(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ193.8,184.9,170.3,148.2,147.3,143.8,143.5,141.0,141.0,140.7,133.0,133.0,131.9,131.9,129.0,129. 0,128.0,128.0,127.4,127.4,118.6,116.2,114.7,112.3,110.2,103.9,84.9,35.1,30.1,23.2,20.4,20.3,12.4,12.1.HRESIMSm / z 567.2033[M+H] + (calcd for C 34 H 32 ClN2O4 + ,567.2051).

[0152] Embodiment 8: 4'-((R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-hydroxy-7-methyl-6,8-dioxo-7,8-dihydroisoquinolin-2(6H)-yl)-[1,1'-biphenyl]-4-carbonitrile (Compound 8) Red powder, yield 69%; mp 113–116℃. 1H NMR(400MHz,CDCl3,J in Hz)δ7.86(s,1H),7.82-7.72(overlapped,6H),7.45(d,J=8.2Hz,2H),7.15(s,1H),7.01(d,J=15.5Hz,1H),5.74-5.64(overlapped,2H),4. 10(s,1H),2.45-2.35(m,1H),1.61(s,3H),1.54(s,3H),1.45-1.38(m,1H),1.35-1.29(m,1H),0.99(d,J=6.6Hz,3H),0.85(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ196.3,188.3,148.7,147.9,145.2,144.0,143.5,141.2,140.6,140.1,133.1,133.1,131.9,129.0,129 .0,128.0,128.0,127.4,127.4,118.6,116.2,115.7,112.4,109.6,101.3,83.7,35.2,30.1,29.6,20.3,12.5,12.1.HRESIMS m / z525.1934[M+H] + (calcd for C 32 H 30 ClN2O3 + ,525.1945).

[0153] Embodiment 9: (R)-5-chloro-2-(4'-cyano-[1,1'-biphenyl]-4-yl)-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl cinnamate (Compound 9) Red powder, yield 48%; mp 135–138℃. 11H NMR (400 MHz, Acetone-d6, J in Hz) δ 8.06 - 8.01 (overlapped, 4H), 7.95 - 7.92 (overlapped, 3H), 7.78 (d, J = 8.1 Hz, 2H), 7.75 - 7.70 (overlapped, 3H), 7.47 - 7.44 (overlapped, 3H), 7.25 - 7.18 (overlapped, 2H), 6.65 (d, J = 16.0 Hz, 1H), 5.86 (d, J = 15.7 Hz, 1H), 5.78 (d, J = 9.8 Hz, 1H), 2.49 - 2.42 (m, 1H), 1.57 (s, 3H), 1.56 (s, 3H), 1.43 - 1.38 (m, 1H), 1.34 - 1.31 (m, 1H), 0.97 (d, J = 6.6 Hz, 3H), 0.83 (t, J = 7.4 Hz, 3H). 13 13C NMR (100 MHz, Acetone-d6) δ 193.6, 184.3, 165.9, 148.8, 147.7, 146.7, 144.7, 144.5, 143.5, 142.2, 142.0, 141.3, 135.3, 133.8, 133.8, 133.8, 133.2, 131.5, 129.9, 129.9, 129.7, 129.7, 129.3, 129.3, 128.9, 128.9, 128.8, 128.8, 119.2, 118.0, 115.2, 112.6, 109.7, 103.2, 86.1, 35.5, 30.7, 23.6, 20.5, 12.4, 12.2. HRESIMS m / z 655.2350 [M + H] + (calcd for C 41 H 36 ClN2O4 + , 655.2364).

[0154] Example 10: (R)-5-chloro-2-(4'-cyano-[1,1'-biphenyl]-4-yl)-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl isonicotinate (Compound 10) Red powder, yield 40%; mp 130–132℃. 1 H NMR(400MHz,Acetone-d6,J in Hz)δ8.86-8.83(overlapped,2H),8.07-8.00(overlapped,5H),7.95-7.90(overlapped,4H),7.83-7.79(overlapped,2H),7.28-7.22(overlapped,2H),5.87(d,J= 15.7Hz,1H),5.79(d,J=9.8Hz,1H),2.50-2.43(m,1H),1.69(s,3H),1.58(s,3H),1 .44-1.38(m,1H),1.34-1.31(m,1H),0.97(d,J=6.6Hz,3H),0.83(t,J=7.4Hz,3H). 13 C NMR (125MHz, Acetone-d6) δ193.2,183.5,164.6,151.8,151.8,149.1,147 .9,145.1,144.5,143.8,142.5,141.9,141.3,137.2,133.8,133.8,133.8, 133.2,129.7,129.7,128.9,128.8,128.8,123.5,123.5,119.2,117.9,115 .1,112.6,109.8,102.8,87.5,35.6,30.7,23.7,20.5,12.4,12.2.HRESIMS m / z 630.2181[M+H] + (calcd for C 38 H 33 ClN3O4 + ,630.2160).

[0155] Embodiment 11: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(4'-methoxy-[1,1'-biphenyl]-4-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl acetate (Compound 11) Red powder, yield 80%; mp 116–119℃. 1H NMR(400MHz,CDCl3,J in Hz)δ7.87(s,1H),7.69(d,J=8.5Hz,2H),7.56(d,J=8.7Hz,2H),7.31(d,J=8.7Hz,2H),7.17(s,1H),7.04–6.95(overlapped,3H),5.71–5.65(overlapped,2H) ),3.87(s,3H),2.44–2.35(m,1H),2.17(s,3H),1.59(s,3H),1.52(s,3H),1.44 -1.37(m,1H),1.34-1.25(m,1H),0.97(d,J=6.6Hz,3H),0.84(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ193.9,184.8,170.3,160.1,147.9,147.7,144.2,143.3,142.7,141.3,138.9,132.0,131.5,128.4,128.4,12 8.2,128.2,126.9,126.9,116.5,114.7,114.7,114.6,110.0,103.4,84.9,55.6,35.1,30.1,23.3,20.4,20.3,12.4,12.1.HRESIMS m / z 572.2217[M+H] + (calcd for C 34 H 35 ClNO5 + ,572.2204).

[0156] Embodiment 12: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-hydroxy-2-(4'-methoxy-[1,1'-biphenyl]-4-yl)-7-methylisoquinoline-6,8(2H,7H)-dione (Compound 12) Red powder, yield 83%; mp 130–131℃. 1H NMR(400MHz,CDCl3,J in Hz)δ7.88(s,1H),7.71(d,J=9.8Hz,2H),7.57(d,J=10.1Hz,2H),7.33(d,J=9.8Hz,2H),7.15(s,2H),7.05-6.99(overlapped,3H),5.75-5.67(overlapped,2H) ),4.12(s,1H),3.88(s,3H),2.45-2.37(m,1H),1.61(s,3H),1.54(s,3H),1.43 -1.38(m,1H),1.35-1.30(m,1H),0.98(d,J=6.6Hz,3H),0.84(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ196.5,188.1,160.2,148.4,148.2,145.6,143.8,142.9,140.4,138.7,132.0,131.5,128.4,128.4,12 8.2,128.2,126.9,126.9,116.4,115.6,114.7,114.7,109.5,100.8,83.7,55.6,35.1,30.1,29.6,20.3,12.5,12.1.HRESIMS m / z 530.2109[M+H] + (calcd for C 32 H 33 ClNO4 + ,530.2098).

[0157] Embodiment 13: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-hydroxy-7-methyl-2-(4-(pyridin-4-yl)phenyl)isoquinoline-6,8(2H,7H)-dione (Compound 13) Red powder, yield 49%; mp 132-133℃. 1H NMR(400MHz,CDCl3,J in Hz)δ8.73(s,2H),7.90-7.79(overlapped,3H),7.62-7.51(overlapped,2H),7.46(d,J=8.3Hz,2H),7.15(s,1H),7.01(d,J=15.6Hz,1H),5.75-5.64(overl apped,2H),4.12(br,1H),2.45-2.36(m,1H),1.61(s,3H),1.54(s,3H),1.45- 1.39(m,1H),1.34-1.29(m,1H),0.98(d,J=6.6Hz,3H),0.85(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ196.4,188.3,150.8,148.7,148.7,147.9,146.3,145.2,144.0,140.9,140.2,140.1,131.9,128 .9,128.9,128.9,127.5,127.5,127.5,116.2,115.7,109.6,101.3,83.7,35.2,30.1,29.6,20.3,12.5,12.1.HRESIMS m / z 501.1951[M+H] + (calcd for C 30 H 30 ClN2O3 + ,501.1945).

[0158] Embodiment 14: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-methyl-6,8-dioxo-2-(4-phenoxyphenyl)-2,6,7,8-tetrahydroisoquinolin-7-yl acetate (Compound 14) Red powder, yield 84%; mp 163–165℃. 1H NMR(500MHz,CDCl3,J in Hz)δ7.82(s,1H),7.42(t,J=7.8Hz,2H),7.22(overlapped,3H),7.14(s,1H),7.09(overlapped,4H),6.96(d,J=15.6Hz,1H),5.67(d,J=9.8Hz,1H),5.63(d, J=15.6Hz,1H),2.49-2.40(m,1H),2.18(s,3H),1.59(s,3H),1.56(s,3H),1.48 -1.36(m,1H),1.35-1.25(m,1H),0.99(d,J=6.6Hz,3H),0.85(t,J=7.4Hz,3H). 13 C NMR (125MHz, CDCl3) δ193.7,184.6,170.1,158.9,155.6,147.9,147.6,143.9,143.1,141.2,134.7,131.7,130.1,130.1,128.0 ,128.0,124.7,119.8,119.8,119.0,119.0,116.1,114.3,109.9,109.8,84.7,34.9,30.0,23.1,20.2,20.1,12.2,11.9.HRESIMS m / z 558.2053[M+H] + (calcd for C 33 H 33 ClNO5 + ,558.2047).

[0159] Embodiment 15: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(4-(4-fluorophenoxy)phenyl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-ylacetate (Compound 15) Red powder, yield 87%; mp123-126℃. 1H NMR(400MHz,CDCl3,J in Hz)δ7.79(s,1H),7.21(d,J=8.8Hz,2H),7.13-7.02(overlapped,7H),6.92(d,J=15.9Hz,1H),5.68-5.59(overlapped,2H),2.45-2. 35(m,1H),2.15(s,3H),1.56(s,3H),1.55(s,3H),1.44-1.36(m,1H),1.35-1.26(m,1H),0.97(d,J=6.6Hz,3H),0.84(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ193.8,184.7,170.2,159.2,158.5(d, 1 J C-F =244.1Hz),151.4,148.0,147.7,144.1,143.3,141.3,134.9,131.9,128.2,128.2,121.7,121.6,118.7, 118.7,117.1,116.8,116.2,114.5,109.9,103.4,84.8,35.1,30.1,23.2,20.3,20.3,12.4,12.0.HRESIMS m / z 576.1962[M+H] + (calcd for C 33 H 32 ClFNO5 + ,576.1953).

[0160] Embodiment 16: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(4-(4-fluorophenoxy)phenyl)-7-hydroxy-7-methylisoquinoline-6,8(2H,7H)-dione (Compound 16) Red powder, yield 64%; mp110-113℃. 1H NMR(400MHz,CDCl3,J in Hz)δ7.81(s,1H),7.26-7.23(overlapped,2H),7.14-7.03(overlapped,7H),6.97(d,J=15.6Hz,1H),5.72-5.62(overlapped,2H),4.10 (s,1H),2.47-2.37(m,1H),1.60(s,3H),1.57(s,3H),1.45-1.39(m,1H),1.35-1.29(m,1H),0.98(d,J=6.6Hz,3H),0.85(t,J=7.4Hz,3H). 13 CNMR(100MHz,CDCl3)δ196.5,188.1,159.4,158.5(d, 1 J C-F =243.1Hz),151.4,148.5,148.3,145.5,143.8,140.4,134.8,131.9,128.2,128.2,121.7,121.6,118. 8,118.8,117.2,116.9,116.2,115.5,109.4,100.8,83.7,35.2,30.1,29.6,20.3,12.4,12.1.HRESIMS m / z534.1855[M+H] + (calcd for C 31 H 30 ClFNO4 + ,534.1847).

[0161] Embodiment 17: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(4-(3-fluorophenoxy)phenyl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-ylacetate (Compound 17) Red powder, yield 77%; mp115-118℃. 1H NMR(400MHz,CDCl3,J in Hz)δ7.82(s,1H),7.40-7.32(m,1H),7.30-7.26(overlapped,2H),7.17-7.12(overlapp ed,3H),6.99-6.89(overlapped,2H),6.87-6.82(m,1H),6.80-6.75(m,1H),5.66(d,J=9 .8Hz,1H),5.59(d,J=15.6Hz,1H),2.45-2.37(m,1H),2.18(s,3H),1.59(s,3H),1.56(s, 3H),1.45-1.38(m,1H),1.34-1.28(m,1H),0.98(d,J=6.6Hz,3H),0.85(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ193.9,184.9,170.4,158.1,148.2,147.7,144.0,143.4,141.3,135.6,131.9,131.1,128.4,128.4,119.9 ,119.9,116.2,115.1,114.5,111.8,111.6,110.0,107.5,107.3,103.6,84.9,35.1,30.1,23.3,20.4,20.3,12.4,12.1.HRESIMS m / z 576.1944[M+H] + (calcd for C 33 H 32 ClFNO5 + ,576.1953).

[0162] Embodiment 18: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(4-(2-methoxyphenoxy)phenyl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-ylacetate (Compound 18) Red powder, yield 89%; mp 133-135℃. 1H NMR(400MHz,CDCl3,J in Hz)δ7.85(s,1H),7.24-6.95(overlapped,10H),5.71-5.64(overlapped,2H),3.84(s,3H),2.49-2.39(m,1H),2.19( s,3H),1.60(s,3H),1.58(s,3H),1.47-1.40(m,1H),1.37-1.30(m,1H),1.00(d,J=6.6Hz,3H),0.87(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ193.9,184.6,170.2,159.4,151.6,147.9,147.8,144.2,143.3,143.2,141.5,134.2,131.9,127.8,127.8,12 6.4,122.2,121.5,117.5,117.5,116.3,114.4,113.1,109.8,103.1,84.8,55.9,35.0,30.1,23.2,20.3,20.3,12.3,12.0.HRESIMS m / z 588.2162[M+H] + (calcd for C 34 H 35 ClNO6 + ,588.2153).

[0163] Embodiment 19: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-hydroxy-2-(4-(2-methoxyphenoxy)phenyl)-7-methylisoquinoline-6,8(2H,7H)-dione (Compound 19) Red powder, yield 41%; mp 139-140℃. 1H NMR(400MHz,CDCl3,J in Hz)δ7.84(s,1H),7.25-7.18(overlapped,3H),7.13-7.09(overlapped,2H),7.06-6.97(overlapped,5H),5.62-5.72(overlapped,2H),4.12(s, 1H),3.82(s,3H),2.46-2.37(m,1H),1.60(s,3H),1.56(s,3H),1.43-1.4 0(m,1H),1.33-1.30(m,1H),0.99(d,J=6.6Hz,3H),0.85(t,J=7.4Hz,3H). 13 C NMR (100MHz, CDCl3) δ193.8,188.1,159.6,151.7,148.4,145.6,143.7,143.4,140.6,136.6,132.0,127.9,127.9,126.5,122. 3,122.3,121.6,117.7,117.7,116.3,113.1,113.1,109.3,100.6,83.7,56.0,35.2,30.1,29.6,20.3,12.4,12.1.HRESIMSm / z 546.2057[M+H] + (calcd for C 32 H 33 ClNO5 + ,546.2047).

[0164] Embodiment 20: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-methyl-2-(4-(naphthalen-2-yl)phenyl)-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-ylcinnamate (Compound 20) Red powder, yield 37%; mp127-130℃. 11H NMR (400 MHz, Acetone-d6, J in Hz) δ 8.05 - 8.00 (overlapped, 3H), 7.87 (d, J = 5.1 Hz, 1H), 7.81 - 7.69 (overlapped, 7H), 7.63 - 7.52 (overlapped, 4H), 7.47 - 7.44 (overlapped, 3H), 7.26 - 7.21 (overlapped, 2H), 6.66 (d, J = 16.1 Hz, 1H), 5.95 (d, J = 15.7 Hz, 1H), 5.79 (d, J = 9.7 Hz, 1H), 2.54 - 2.46 (m, 1H), 1.66 (s, 3H), 1.59 (s, 3H), 1.45 - 1.40 (m, 1H), 1.36 - 1.32 (m, 1H), 0.98 (d, J = 6.7 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H). 13 13C NMR (100 MHz, Acetone-d6) δ 193.7, 184.2, 165.9, 148.9, 147.7, 146.7, 144.8, 143.4, 143.2, 142.3, 140.9, 139.4, 135.3, 134.9, 133.2, 132.4, 132.4, 132.2, 131.5, 129.9, 129.9, 129.4, 129.3, 129.3, 129.3, 128.1, 128.1, 128.0, 127.4, 127.0, 126.4, 126.1, 118.1, 118.0, 115.2, 109.7, 103.0, 86.1, 35.6, 30.7, 23.6, 20.5, 12.4, 12.2. HRESIMS m / z 680.2546 [M+H] + (calcd for C 44 H 39 ClNO4 + , 680.2562).

[0165] Example 21: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-methyl-2-(4-(naphthalen-2-yl)phenyl)-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-ylisonicotinate (Compound 21) Red powder, yield 35%; mp134-136℃. 1 H NMR(400MHz,Acetone-d6,J in Hz)δ8.84(d,J=6.0Hz,2H),8.09(s,1H),8.02(t,J=7.6Hz,2H),7.91(d,J=6.0Hz,2H),7.86(d,J =8.4Hz,1H),7.83-7.75(overlapped,4H),7.65-7.61(m,1H),7.59-7.50(m,3H),7.29-7.23(ov erlapped,2H),5.96(d,J=15.7Hz,1H),5.81(d,J=9.7Hz,1H),2.54-2.46(m,1H),1.71(s,3H),1 .66(s,3H),1.46-1.40(m,1H),1.36-1.31(m,1H),0.99(d,J=6.7Hz,3H),0.85(t,J=7.4Hz,3H). 13 C NMR (100MHz, Acetone-d6) δ193.3,183.5,164.6,151.8,151.8,149.2,147.9,14 5.2,143.7,143.3,142.6,140.8,139.4,137.2,134.9,133.3,132.4,132.4,132 .2,129.4,129.3,128.1,128.1,128.0,127.4,127.0,126.4,126.1,123.5,123. 5,118.0,115.1,109.8,102.6,87.6,35.6,30.7,23.7,20.5,12.4,12.2.HRESIMS m / z 655.2352[M+H] + (calcd for C 41 H 36 ClN2O4 + ,655.2358).

[0166] Embodiment 22: (R)-2-([1,1':4',1”-terphenyl]-4-yl)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl acetate (Compound 22) Red powder, yield 52%; mp 130-133℃. 1 H NMR(400MHz,Acetone-d6,J in Hz)δ8.00(d,J=8.7Hz,2H),7.93(s,1H),7.89(d,J=8.4Hz,2H),7.82(d,J=8.4Hz,2H),7.76–7 .71(m,4H),7.50(t,J=7.7Hz,2H),7.42–7.38(m,1H),7.19(d,J=15.7Hz,1H),7.16(s,1H),5. 86(d,J=15.7Hz,1H),5.77(d,J=9.7Hz,1H),2.48–2.41(m,1H),2.07(s,3H),1.57(s,3H),1.4 8(s,3H),1.42–1.38(m,1H),1.34–1.32(m,1H),0.97(d,J=6.6Hz,3H),0.83(t,J=7.4Hz,3H). 13 C NMR (100MHz, Acetone-d6) δ193.7,184.3,170.0,148.9,147.6,144.7,143.4 ,142.7,142.2,141.7,141.0,140.9,139.0,133.2,129.9,129.9,129.1,129 .1,128.5,128.5,128.5,128.4,128.4,128.4,128.4,128.4,127.7,127.7,1 18.0,115.1,109.6,86.0,35.5,30.7,23.5,20.5,20.2,12.4,12.2.HRESIMS m / z 618.2398[M+H] + (calcd for C 39 H 37 ClNO4 + ,618.2406).

[0167] Embodiment 23: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(isonicotinamido)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-ylacetate (Compound 23) Red powder, yield 70%; mp149-152℃. 1 H NMR(500MHz,CDCl3,J in Hz)δ8.81(s,2H),7.91-7.80(overlapped,3H),7.05-6.97(overlapped,2H),6.24(d,J=15.6Hz,1H),5.71(d,J=9.6Hz,1H),2.47-2. 40(m,1H),2.00(s,3H),1.72(s,3H),1.51(s,3H),1.44-1.38(m,1H),1.34-1.28(m,1H),0.97(d,J=6.6Hz,3H),0.85(t,J=7.4Hz,3H). 13 C NMR (125MHz, CDCl3) δ192.2,184.7,170.9,165.0,151.0,151.0,150.2,149.4,145.8,145.5,142.8,132.3 ,132.3,121.6,121.6,121.6,115.4,113.2,109.3,85.5,35.2,30.1,23.4,20.4,20.3,12.6,12.1.HRESIMS m / z 510.1784[M+H] + (calcd for C 27 H 29 ClN3O5 + ,510.1790).

[0168] Embodiment 24: N-((R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-7-hydroxy-7-methyl-6,8-dioxo-7,8-dihydroisoquinolin-2(6H)-yl)isonicotinamide (Compound 24) Red powder, yield 61%; mp 136-138℃. 1H NMR(400MHz,Acetone-d6,J in Hz)δ8.85(s,2H),8.08(s,1H),7.96(d,J=6.1Hz,2H),7.27(d,J=15.7Hz,1H),7.09(s,1H),6.45(d,J=15.7Hz,1H),5.80(d,J=9.7Hz, 1H),2.55-2.43(m,1H),1.76(s,3H),1.46(s,3H),1.44-1.36(m,1H),1.34-1.30(m,1H),0.97(d,J=6.6Hz,3H),0.83(t,J=7.4Hz,3H). 13 C NMR NMR (100MHz, Acetone-d6) δ196.4,188.5,165.7,151.6,151.6,151.6,150.3,148.5,145.4,145.3,143. 0,139.2,133.4,133.4,122.4,122.4,116.3,114.7,108.5,102.3,84.0,35.6,20.5,12.6,12.2.HRESIMS m / z 468.1686[M+H] + (calcd for C 25 H 27 ClN3O4 + ,468.1685).

[0169] Embodiment 25: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(isonicotinamido)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-ylcinnamate (Compound 25) Red powder, yield 55%; mp150-151℃. 1H NMR(400MHz,Methanol-d4,J in Hz)δ8.84(s,2H),8.18(s,1H),8.05(d,J=5.5Hz,2H),7.62(d,J=16.0Hz,1H),7.58–7.52(m ,2H),7.37–7.33(overlapped,3H),7.21(s,1H),7.14(d,J=15.7Hz,1H),6.54(d,J=16.0Hz ,1H),6.24(d,J=15.7Hz,1H),5.71(d,J=9.8Hz,1H),2.46-2.38(m,1H),1.70(s,3H),1.55( s,3H),1.41–1.35(m,1H),1.30–1.23(m,1H),0.92(d,J=6.6Hz,3H),0.79(t,J=7.4Hz,3H). 13 C NMR(100MHz,Methanol-d4)δ193.9,186.1,167.2,166.1,151.3,150.4,150.4,150.0,148.0,146.8,146.8,144.4,141.8,135.5,133.7, 131.9,130.1,130.1,130.1,129.5,129.5,123.8,117.4,116.7,114.3,110.4,103.9,86.1,36.3,31.1,23.7,20.5,12.6,12.3.HRESIMS m / z 598.2107[M+H] + (calcd for C 34 H 33 ClN3O5 + ,598.2103).

[0170] Embodiment 26: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(isonicotinamido)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl(E)-3-(thiophen-3-yl)acrylate (Compound 26) Red powder, yield 48%; mp125-128℃. 1H NMR(400MHz,Acetone-d6,J in Hz)δ9.03-8.99(m,2H),8.29-8.25(m,2H),8.03(s,1H),7.90-7.88(m,1H),7.79(d,J=15.7Hz ,1H),7.58-7.56(m,1H),7.49-7.46(m,1H),7.30(d,J=15.8Hz,1H),7.17(s,1H),6.77(d,J=1 5.8Hz,1H),6.45(d,J=15.8Hz,1H),5.82(d,J=9.7Hz,1H),2.54-2.47(m,1H),1.82(s,3H),1. 72(s,3H),1.43-1.40(m,1H),1.36-1.33(m,1H),0.98(d,J=6.7Hz,3H),0.84(t,J=7.4Hz,3H). 13 C NMR (150MHz, Acetone-d6) δ192.6,183.3,166.0,163.3,150.6,148.5,147.7,145.2,144.9,144.5,138.6,138.2,133.5,130.1, 128.4,128.4,126.1,125.8,125.8,117.4,115.0,115.0,108.9,103.3,88.1,55.0,35.6,30.7,23.7,20.5,12.6,12.2.HRESIMS m / z 604.1662[M+H] + (calcd for C 32 H 31 ClN3O5S + ,604.1667).

[0171] Embodiment 27: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(isonicotinamido)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-ylisonicotinate (Compound 27) Red powder, yield 50%; mp143-145℃. 1H NMR(400MHz,Acetone-d6,J in Hz)δ8.83(s,4H),8.22(s,1H),7.94-7.88(overlapped,4H),7.29(d,J=15.7Hz,1H),7.18(s,1H),6.45(d,J=15.7Hz,1H),5.82(d,J=9.8 Hz,1H),2.54-2.47(m,1H),1.76(s,3H),1.70(s,3H),1.44-1.38(m,1H),1.36-1.30(m,1H),0.98(d,J=6.7Hz,3H),0.84(t,J=7.4Hz,3H). 13 C NMR (100MHz, Acetone-d6) δ192.7,183.8,165.8,164.6,151.8,151.8,151.8,151.7,151.7,150.2,148.7,145.4,145.4,144 .6,144.1,139.3,137.0,133.3,123.5,122.3,115.4,114.6,109.1,103.7,87.3,35.6,30.7,23.6,20.5,12.6,12.2.HRESIMS m / z573.1901[M+H] + (calcd for C 31 H 30 ClN4O5 + ,573.1899).

[0172] Embodiment 28: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(isonicotinamido)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yl 1H-pyrazole-5-carboxylate (Compound 28) Red powder, yield 23%; mp143-145℃. 1H NMR(400MHz,Acetone-d6,J in Hz)δ11.19(s,1H),8.82–8.77(m,1H),8.05(s,1H),7.94(d,J=2.4Hz,1H),7.90-7.86(m,1 H),7.79(d,J=2.4Hz,1H),7.28(d,J=15.8Hz,1H),7.15(s,1H),6.94–6.83(overlapped,2 H),6.41(d,J=15.8Hz,1H),5.80(d,J=9.8Hz,1H),2.51–2.46(m,1H),1.72(s,3H),1.63(s ,3H),1.45–1.40(m,1H),1.33–1.30(m,1H),0.97(d,J=6.6Hz,3H),0.83(t,J=7.4Hz,3H). 13 C NMR (150MHz, Acetone-d6) δ193.1,184.4,166.4,161.7,151.5,150.3,148.2,148.2,144.8,144.3,144.3,133.3,133 .3,133.3,123.8,123.8,115.3,115.0,109.3,108.9,108.9,107.3,86.1,35.6,30.7,23.6,20.5,12.5,12.2.HRESIMS m / z 562.1831[M+H] + (calcd for C 29 H 29 ClN5O5 + ,562.1852).

[0173] Embodiment 29: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(isonicotinamido)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-yloxazole-4-carboxylate (Compound 29) Red powder, yield 43%; mp143-145℃. 1H NMR (400 MHz, Acetone-d6, J in Hz)δ8.85–8.82(m,2H),8.73(d,J=1.0Hz,1H),8.32(d,J=1.0Hz,1H),8.18(s, 1H),7.94–7.92(m,2H),7.30(d,J=15.8Hz,1H),7.16(s,1H),6.46(d,J=15.8Hz ,1H),5.82(d,J=9.8Hz,1H),2.53–2.48(m,1H),1.77(s,3H),1.63(s,3H),1.45 –1.42(m,1H),1.39–1.35(m,1H),0.98(d,J=6.6Hz,3H),0.83(t,J=7.4Hz,3H). 13 C NMR (150MHz, Acetone-d6) δ193.0,184.1,165.8,160.2,153.4,151.7,151.7,150.0,148.4,146.6,145.2,144.2,144 .0,139.3,133.4,133.0,122.3,122.3,115.4,114.8,109.0,104.0,86.6,35.6,30.7,23.7,20.5,12.6,12.2.HRESIMS m / z 563.1712[M+H] + (calcd for C 29 H 28 ClN4O6 + ,563.1692).

[0174] Embodiment 30: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(isonicotinamido)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-ylthiazole-4-carboxylate (Compound 30) Red powder, yield 50%; mp142-143℃. 1H NMR (400 MHz, Acetone-d6, J in Hz)δ9.03(d,J=2.0Hz,1H),8.86-8.77(m,2H),8.59(d,J=2.0Hz,1H),8.21(s,1 H),7.91(d,J=6.0Hz,2H),7.28(d,J=15.7Hz,1H),7.16(s,1H),6.43(d,J=15.7H z,1H),5.82(d,J=9.7Hz,1H),2.55–2.42(m,1H),1.76(s,3H),1.66(s,3H),1.4 5–1.37(m,1H),1.34–1.29(m,1H),0.97(d,J=6.6Hz,3H),0.84(t,J=7.4Hz,3H). 13 C NMR (100MHz, Acetone-d6) δ192.9,184.3,165.8,160.5,155.7,151.6,151.6,150.4,148.5,147.5,145.4,144.7,144 .1,139.2,133.4,130.4,122.3,122.3,115.5,114.7,109.1,103.7,86.7,35.6,30.7,23.7,20.5,12.6,12.2.HRESIMS m / z 579.1456[M+H] + (calcd for C 29 H 28 ClN4O5S + ,579.1469).

[0175] Embodiment 31: (R)-5-chloro-3-((S,1E,3E)-3,5-dimethylhepta-1,3-dien-1-yl)-2-(isonicotinamido)-7-methyl-6,8-dioxo-2,6,7,8-tetrahydroisoquinolin-7-ylquinoline-6-carboxylate (Compound 31) Red powder, yield 50%; mp156-159℃. 1H NMR(400MHz,Methanol-d4,J in Hz)δ9.01-8.98(m,1H),8.80-8.78(m,1H),8.76-8.70(m,2H),8.55(d,J=8.9Hz,1H),8.36-8.32(m,1 H),8.21(s,1H),8.12(d,J=8.9Hz,1H),7.97-7.92(overlapped,2H),7.67-7.63(m,1H),7.41(s,1H) ,7.24(d,J=15.8Hz,1H),6.48(d,J=15.8Hz,1H),5.79(d,J=9.8Hz,1H),2.54-2.48(m,1H),1.78(s,3 H),1.77(s,3H),1.48-1.43(m,1H),1.37-1.33(m,1H),1.01(d,J=6.7Hz,3H),0.88(t,J=7.4Hz,3H). 13 C NMR(150MHz,Methanol-d4)δ194.6,184.4,173.6,166.1,153.9,151.7,150.9,150.9,149.3,147.7,145.9,143.8,139.9,133.8,133.0,133 .0,130.4,130.4,129.8,129.8,129.1,128.8,123.6,123.5,123.5,116.8,115.6,110.8,87.0,36.3,31.2,24.0,20.6,12.6,12.3.HRESIMS m / z 623.2048[M+H] + (calcd for C 35 H 32 ClN4O5 + ,623.2061).

[0176] Example 32: Anti-mycobacterial test Purpose of the experiment: To test the inhibitory effect of the compounds on Mycobacterium tuberculosis, Mycobacterium marinum and Mycobacterium smegmatis.

[0177] 1) Test strains: Mycobacterium tuberculosis ATCC 25177, Mycobacterium marinum and Mycobacterium smegmatis.

[0178] 2) Detection method: Inoculate 198 μL of 1000-fold diluted mycobacterial solution (OD 550 The value is about 0.225~0.275), and then add 2μL of the prepared compound working solution. The test plate was placed in a 37°C incubator for 10~12 days. Then, 12.5μL 7H9+20% Tween 80 medium and 20μL Alamar blue solution were added and cultured for 24 hours. DMSO was used as a solvent and growth control. 200μL of culture medium was placed in the wells around the test plate as a culture medium control. Rifampicin and isoniazid were used as positive controls and measured three times in parallel.

[0179] MIC 90 Determination of the value: Observe the color change of Alamar blue by naked eyes, or judge whether the bacteria grow by fluorescence detection (Ex / Em, 530nm / 590nm), so as to determine the inhibition rate and MIC 90 value.

[0180] result: Table 1 Inhibitory effect of the compounds of the present invention on mycobacteria Note 1: In the table, "A" indicates MIC for M. tuberculosis activity 90 Value is less than or equal to 1μM, "B" indicates MIC 90 The value is between 1-15μM, "C" represents MIC 90 The value is between 15-25μM, "D" indicates MIC 90 The value is greater than 25 μM; in the activity of Mycobacterium marinum, "A" indicates MIC 90 The value is between 10-40μM, "B" indicates MIC 90 The value is between 40-80μM, "C" indicates MIC 90 The value is between 80-100 μM, "D" indicates MIC 90 Values ​​greater than 100 μM; in M. smegmatis, “A” indicates MIC 90 Values ​​range from 1-15μM, "B" indicates MIC 90 The value is between 15-30μM, "C" represents MIC 90 The value is between 30-50μM, "D" indicates MIC 90 The value is greater than 50 μM. In addition, the present invention tested the activities of compounds A, B, C, D, E, F, G, H, I, J, K, L, and M against three mycobacteria in parallel. Note 2: The present invention also tests the compounds in which R1 is aliphatic hydrocarbon, phenyl and heterocyclic ring substituted in the preparation process, namely compound A Compound B Compound C Compound D Compound E Compound F Compound G Compound H Compound I Compound J Compound K Compound L Compound M For comparison.

[0181] After in vitro activity screening on three strains of mycobacteria, the compounds of the present invention showed strong antibacterial activity against the three strains of mycobacteria, which was superior to positive drugs isoniazid and rifampicin or equivalent to positive drugs to a certain extent, and significantly superior to compounds A, B, C, D, E, F, G, H, I, J, K, L, and M. Therefore, the compounds of the present invention have great potential application prospects in inhibiting the growth of mycobacteria.

[0182] Example 33: Other antimicrobial activity tests Purpose of the experiment: To test the antibacterial effect of the compound on other Gram-negative bacteria, Gram-negative bacteria and fungi, and to study whether the compound of the present invention selectively inhibits the growth of mycobacteria.

[0183] 1) Test strains: Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Candida Albicans

[0184] 2) Detection method: The bacteria were picked from the solid culture medium and cultured in a breathable culture bottle at 37°C until the logarithmic growth phase with a density of 1.0×10 7 Before testing the activity, dilute it in the culture medium to 1:25 (4×10 5 / ml). Prepare the sample solution with DMSO and filter it with a 0.22μm filter membrane for later use. When testing, add 198μL of culture medium to the first row of the 96-well plate, and the volume of bacterial solution in the remaining wells is 100μL. Add 2μL of the sample solution to each well in the first row, dilute it to 8 concentrations in an equal gradient, and then add 100μL of bacterial solution to each well. After culturing at 32℃ for 60 hours, observe from the back of the 96-well plate with the naked eye and record the concentration of the wells in the last row of clarity, which is the minimum inhibitory concentration MIC.90 The experiment used ciprofloxacin and amphotericin B as positive controls, DMSO as blank control, and bacterial solution as negative control, and three parallel experiments were set up.

[0185] MIC 90 Determination of value: Observe from the back of the 96-well plate with the naked eye and record the clear wells to determine whether the bacteria grow, thereby determining the inhibitory effect and MIC 90 value.

[0186] result: At a concentration of 50 μM, compounds 1-31 of the present invention had no significant activity against the four strains tested.

[0187] Through in vitro screening of the activity of four other Gram-negative bacteria, Gram-negative bacteria and fungi, combined with Example 32, the compounds of the present invention have a strong mycobacterial inhibitory activity, which is superior to the positive drugs isoniazid and rifampicin to a certain extent or is equivalent to the positive drugs, and has a certain selectivity and is ineffective against other fungi and bacteria. Therefore, the compounds of the present invention have good potential application prospects in selectively inhibiting the growth of mycobacteria.

[0188] Example 34: Combined drug sensitivity test Purpose of the experiment: To test the combined effect of the compound and the positive control isoniazid on Mycobacterium marinum when used in combination, and to study whether the compound of the present invention has the potential to be used in combination with the positive control.

[0189] 2) Detection method: According to the checkerboard method test, the MIC data of the compound and isoniazid were used as the design basis. The two drug concentrations of 4*MIC, 2*MIC, MIC, 1 / 2*MIC, 1 / 4*MIC, 1 / 8*MIC and 1 / 16*MIC were combined for 7x7 in a 96-well plate added with bacterial solution using the checkerboard dilution method. The 96-well plate was placed in a constant temperature incubator at 32°C. After 48 hours, the results were observed and recorded, and the measurement was repeated three times for each well.

[0190] The graded inhibitory concentration index (FICI) was used to evaluate the combined effect. The formula is as follows: If the minimum inhibitory concentration of drug A when used in combination is recorded as MIC A The minimum inhibitory concentration of drug B when used in combination is recorded as MIC B , the MICs of the two drugs when used alone are recorded as A and B respectively. Then, its calculation formula is as follows: FICI = MIC A / A+MIC B / B. The determination of the combined effect is as follows: ①FICI≤0.5, synergistic effect; ②0.5<FICI≤1, additive effect; ③1<FICI≤2, irrelevant; ④FICI>2, antagonistic effect.

[0191] result: Table 2 The combined effect of the compounds of the present invention and isoniazid on Mycobacterium marinum Compound FICI Compound FICI Compound FICI Compound FICI 1 C 12 A 23 A Compound C D 2 B 13 A 24 A Compound D D 3 B 14 C 25 A Compound E D 4 A 15 B 26 A Compound F D 5 B 16 B 27 A Compound G D 6 B 17 A 28 B Compound H D 7 A 18 A 29 A Compound I D 8 B 19 A 30 A Compound J D 9 B 20 A 31 A Compound K D 10 A 21 A Compound A D Compound L D 11 B 22 A Compound B D Compound M D Note: "A" in the table means FICI value is less than or equal to 0.5, "B" means IC 50 The value is between 0.5-1μM, "C" represents IC 50 The value is between 1 and 2, and "D" indicates that the FICI value is greater than 2. In addition, the present invention tests in parallel the combined effects of compounds A, B, C, D, E, F, G, H, I, J, K, L, and M in combination with isoniazid on Mycobacterium marinum.

[0192] After the evaluation of the combined effect, the compounds of the present invention can produce a more significant synergistic or additive effect when used in combination with isoniazid, and compounds A, B, C, D, E, F, G, H, I, J, K, L, and M cannot produce a synergistic effect. Therefore, the compounds of the present invention have great potential application prospects in the combined use with positive drugs.

[0193] In summary, the compounds of the present invention have excellent selective inhibition of mycobacterial growth activity and can produce significant synergistic effects when used in combination with positive drugs, and have further research value and broad development prospects.

[0194] Finally, it should be noted that there are other ways to implement the present invention. Accordingly, the embodiments of the present invention are described as examples, but are not limited to the contents described in the present invention, and may also be modified within the scope of the present invention or added to the claims. All publications or patents cited in the present invention will be used as references of the present invention.

Claims

1. A (+)-sclerotiorin derivative, characterized in that is a compound represented by formula (I) or a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, ester, pharmaceutically acceptable salt or prodrug thereof of the compound represented by formula (I), in: R1 is a substituted or unsubstituted biphenyl, biphenyl ether, terphenyl, 4-(1-naphthyl)phenyl or 4-pyridineamide fragment, wherein the benzene ring and the pyridine ring can be independently and optionally substituted by 1, 2, 3 or 4 groups selected from deuterium, F, Cl, Br, I, hydroxyl, amino, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 3-6 R2 is substituted by a cycloalkyl, a 3-6 membered heterocyclic group, an aryl or a 5-6 membered heteroaryl substituent. R2 is substituted or unsubstituted cinnamate, pyridine acrylate, heterocyclic acrylate, benzoate, pyridine carboxylate and heterocyclic carboxylate, wherein the benzene ring and the pyridine ring can be independently and optionally substituted by 1, 2, 3 or 4 groups selected from deuterium, F, Cl, Br, I, hydroxyl, amino, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, C 3-6 The substituents are substituted by cycloalkyl, 3-6 membered heterocyclyl, aryl or 5-6 membered heteroaryl.

2. The compound according to claim 1, wherein R1 is R2 is hydroxyl, acetoxy, substituted or unsubstituted 3. The compound according to claim 1, characterized in that Having one of the following structures or its stereoisomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs:

4. A pharmaceutical composition, characterized in that Comprising the compound according to any one of claims 1 to 3.

5. The pharmaceutical composition according to claim 4, characterized in that It further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, solvent or a combination thereof.

6. A combination of a compound according to any one of claims 1 to 3 or a pharmaceutical composition according to any one of claims 4 to 5, and one or more therapeutically active agents. It is characterized in that The combination drug comprises one or more drugs for preventing or treating mycobacterium bacterial infectious diseases, wherein the active ingredients of the drugs are different from the compounds disclosed in the present invention, specifically rifampicin, isoniazid, ethambutol, putomanid, bedaquiline, triclosan, streptomycin, pyrazinamide, para-aminosalicylic acid, ethionamide, capreomycin, rifadin, delamanid and linezolid.

7. Use of the compound according to any one of claims 1 to 3 or the pharmaceutical composition according to any one of claims 4 to 6 for preparing a medicament for treating mammals infected by Mycobacterium bacteria, including humans.

8. The use according to claim 7, wherein the Mycobacterium bacteria include Mycobacterium tuberculosis, Mycobacterium marinum and Mycobacterium smegmatis.

9. The use according to claim 7, wherein the mycobacterium bacterial infectious disease is pulmonary tuberculosis, bone tuberculosis, lymph node tuberculosis, lumbar tuberculosis, thoracic tuberculosis, breast tuberculosis, swimming pool granuloma, lung infection, lymph node infection, Buruli ulcer.